<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">BMC Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">BMC Bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>BMC Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1471-2105</issn>
    <publisher>
      <publisher-name>BioMed Central</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9281118</article-id>
    <article-id pub-id-type="publisher-id">4788</article-id>
    <article-id pub-id-type="doi">10.1186/s12859-022-04788-7</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>DriverRWH: discovering cancer driver genes by random walk on a gene mutation hypergraph</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" equal-contrib="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5033-5376</contrib-id>
        <name>
          <surname>Wang</surname>
          <given-names>Chenye</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8442-0288</contrib-id>
        <name>
          <surname>Shi</surname>
          <given-names>Junhan</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0919-7386</contrib-id>
        <name>
          <surname>Cai</surname>
          <given-names>Jiansheng</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3842-1153</contrib-id>
        <name>
          <surname>Zhang</surname>
          <given-names>Yusen</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1832-4404</contrib-id>
        <name>
          <surname>Zheng</surname>
          <given-names>Xiaoqi</given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0800-0016</contrib-id>
        <name>
          <surname>Zhang</surname>
          <given-names>Naiqian</given-names>
        </name>
        <address>
          <email>nqzhang@email.sdu.edu.cn</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.27255.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 1761 1174</institution-id><institution>School of Mathematics and Statistics, </institution><institution>Shandong University, </institution></institution-wrap>Weihai, 264209 China </aff>
      <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.469274.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1761 1246</institution-id><institution>Department of Mathematics, </institution><institution>Weifang University, </institution></institution-wrap>Weifang, 261061 Shandong China </aff>
      <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.412531.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 0701 1077</institution-id><institution>Department of Mathematics, </institution><institution>Shanghai Normal University, </institution></institution-wrap>Shanghai, 200234 China </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>13</day>
      <month>7</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>13</day>
      <month>7</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <volume>23</volume>
    <elocation-id>277</elocation-id>
    <history>
      <date date-type="received">
        <day>21</day>
        <month>12</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>8</day>
        <month>6</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Â© The Author(s) 2022</copyright-statement>
      <license>
        <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <sec>
        <title>Background</title>
        <p id="Par1">Recent advances in next-generation sequencing technologies have helped investigators generate massive amounts of cancer genomic data. A critical challenge in cancer genomics is identification of a few cancer driver genes whose mutations cause tumor growth. However, the majority of existing computational approaches underuse the co-occurrence mutation information of the individuals, which are deemed to be important in tumorigenesis and tumor progression, resulting in high rate of false positive.</p>
      </sec>
      <sec>
        <title>Results</title>
        <p id="Par2">To make full use of co-mutation information, we present a random walk algorithm referred to as DriverRWH on a weighted gene mutation hypergraph model, using somatic mutation data and molecular interaction network data to prioritize candidate driver genes. Applied to tumor samples of different cancer types from The Cancer Genome Atlas, DriverRWH shows significantly better performance than state-of-art prioritization methods in terms of the area under the curve scores and the cumulative number of known driver genes recovered in top-ranked candidate genes. Besides, DriverRWH discovers several potential drivers, which are enriched in cancer-related pathways. DriverRWH recovers approximately 50% known driver genes in the top 30 ranked candidate genes for more than half of the cancer types. In addition, DriverRWH is also highly robust to perturbations in the mutation data and gene functional network data.</p>
      </sec>
      <sec>
        <title>Conclusion</title>
        <p id="Par3">DriverRWH is effective among various cancer types in prioritizes cancer driver genes and provides considerable improvement over other tools with a better balance of precision and sensitivity. It can be a useful tool for detecting potential driver genes and facilitate targeted cancer therapies.</p>
      </sec>
      <sec>
        <title>Supplementary Information</title>
        <p>The online version contains supplementary material available at 10.1186/s12859-022-04788-7.</p>
      </sec>
    </abstract>
    <kwd-group xml:lang="en">
      <title>Keywords</title>
      <kwd>Cancer driver genes</kwd>
      <kwd>Somatic mutation</kwd>
      <kwd>Gene network</kwd>
      <kwd>Hypergraph model</kwd>
      <kwd>Random walk</kwd>
      <kwd>Candidate gene prioritization</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id>
            <institution>National Natural Science Foundation of China</institution>
          </institution-wrap>
        </funding-source>
        <award-id>12071351</award-id>
        <award-id>61877064</award-id>
        <award-id>61972257</award-id>
        <award-id>62072277</award-id>
        <principal-award-recipient>
          <name>
            <surname>Cai</surname>
            <given-names>Jiansheng</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Yusen</given-names>
          </name>
          <name>
            <surname>Zheng</surname>
            <given-names>Xiaoqi</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Naiqian</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>Â© The Author(s) 2022</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Background</title>
    <p id="Par16">Cancer is a complex genetic disease characterized by abnormal and uncontrolled cellular growth, which is caused primarily by the accumulation of genomic alterations that together enable malignant growth [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Recent advances in next-generation sequencing (NGS) technologies have generated massive amounts of cancer genomic data, such as The Cancer Genome Atlas (TCGA), which provides somatic mutation landscapes to better characterize the molecular signatures of cancer [<xref ref-type="bibr" rid="CR3">3</xref>]. There is a consensus viewpoint on tumorigenesis that only a few mutational events occurring in a set of genes (called âcancer driver genesâ) affect the homeostatic development of a set of key cellular functions [<xref ref-type="bibr" rid="CR4">4</xref>â<xref ref-type="bibr" rid="CR6">6</xref>]. Discovery of these cancer driver genes across various tumor types is a key step in understanding tumor biology and developing targeted anticancer therapies.</p>
    <p id="Par17">A number of computational tools have been developed to identify cancer driver genes from multidimensional genomic data. Most of these tools can be classified into three categories based on their basic principles [<xref ref-type="bibr" rid="CR7">7</xref>]. Frequency-based approaches define that the most commonly occurring mutation are more likely to be drivers, such as MutSigCV and MuSic [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Unfortunately, methods based on frequency are underpowered for uncovering low recurrently driver genes [<xref ref-type="bibr" rid="CR10">10</xref>]. Functional impact-based approaches, such as OncodriveFM, integrate multiple-domain information to predict the functional impact of single nucleotide variants (SNVs) [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. However, most of these methods use machine learning based models. Building either a gold-standard positive data set or a negative data set for such model is a difficult task, and that restricts the use of these methods [<xref ref-type="bibr" rid="CR10">10</xref>]. The third category is network-based methods enlightened by the observation that mutations in a cancer genome tend to converge on a few biological pathways, attempt to identify groups of driver genes based on prior knowledge of pathways and proteins or genetic interactions [<xref ref-type="bibr" rid="CR13">13</xref>â<xref ref-type="bibr" rid="CR17">17</xref>]. A tool named DawnRank adopts PageRank algorithm to rank potential drivers based on their impact on the overall differential expression of the downstream genes [<xref ref-type="bibr" rid="CR14">14</xref>]. HotNet2 uses a random walk with restart algorithm for identification of mutated subnetworks, in which the mutation frequency of each gene and the frequencies of its network neighbors are considered and hub genes are often yielded with highly predicted scores [<xref ref-type="bibr" rid="CR15">15</xref>]. This kind of methods have advantages in their ability to identify driver genes with low recurrence and improve the accuracy of predicting driver genes to some extent [<xref ref-type="bibr" rid="CR18">18</xref>].</p>
    <p id="Par18">Despite the rapid progress in computational approaches to prioritize cancer driver genes with the advent of next-generation sequencing technologies, the false positive rates of these existing methods are still too high. In addition, there are evidences showing that driver gene co-occurring may play a key role in cancer initiation and progression [<xref ref-type="bibr" rid="CR19">19</xref>â<xref ref-type="bibr" rid="CR21">21</xref>]. Because the activation or inactivation of one given driver gene is usually not sufficient to induce tumorigenesis, multiple mutations in different driver genes have to cooperate to gradually transform normal cells into precursor lesions and subsequently invasive and metastatic cancer [<xref ref-type="bibr" rid="CR22">22</xref>â<xref ref-type="bibr" rid="CR25">25</xref>]. Among majority of the published methods, the practice of putting single gene mutation frequency as input information could result in the loss of all the co-occurring alternations information of the individual tumors. In this study, we introduced a weighted hypergraph model and present a novel tool DriverRWH by integrating mutation profile and PPI network data to predict driver genes. Hypergraph is a generalization of simple graphs where its edges, called hyperedges, are allowed to connect arbitrary number of vertices, which makes it suitable for representation of high-order relations and it can be used to model biology network, data structure, computations and a variety of other systems [<xref ref-type="bibr" rid="CR26">26</xref>â<xref ref-type="bibr" rid="CR28">28</xref>]. Herein, we adopted hyperedges to represent the co-exist relationship among mutated genes in individuals, so the problem of information loss of co-occurring alternations can be avoided in a certain extent. We next specified the weights of mutated genes in each hyperedge according their interaction in PPI network and construct the weighted hypergraph. Thereafter, we generalized a random walk algorithm to the weighted hypergraph. Finally, we ranked all the candidate mutated genes for the given cancer type. To verify our method, we applied DriverRWH to 31 cancer types from TCGA and found that our method outperforms the state-of-the-art tools for the majority of cancer types regardless of which reference network we use. We also evaluated the robustness of our method and found that DriverRWH is highly robust to various data perturbations.</p>
  </sec>
  <sec id="Sec2">
    <title>Methods</title>
    <sec id="Sec3">
      <title>Overview</title>
      <p id="Par19">In this study, we proposed DriverRWH, which uses random walk on weighted hypergraph to prioritize the driver genes (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>). Firstly, for a given cancer type, a hypergraph was constructed basing on mutation profile, wherein tumor samples are presented as hyperedges and mutant genes are presented as vertices. Secondly, according to our hypothesis that a gene is more likely to be a driver gene if it is highly associated with other mutated genes, we differentiated genes within a hyperedge of sample in accordance with their degrees in the corresponding subnetwork of the PPI network. Then, we adopted a probabilistic weighted random walk that take advantage of the hypergraph structure, and carried out this iteratively. After some steps, the random walk would stabilize, producing a score for each mutated gene. At last, all candidate mutant genes are ranked in descending order based on their score.<fig id="Fig1"><label>Fig. 1</label><caption><p>Overview of DriverRWH. <bold>A</bold>, <bold>B</bold> Construction of the weighted hypergraph model using somatic mutation profiles of a given cancer type and a PPI network. Each sample is indicated with colored circular area (hyperedge) which contains all the mutated genes (vertices) of individual. Since the number of mutated gene varies from samples, the hypergraph contains different number of vertices. The weights of vertices in each hyperedge are assigned according to the degree in the context of the background subnetwork. <bold>C</bold> Illustration of the random walk process on the hypergraph. For vertex <inline-formula id="IEq43"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$u$$\end{document}</tex-math><mml:math id="M2"><mml:mi>u</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq43.gif"/></alternatives></inline-formula>, we randomly select a hyperedge which incident with <inline-formula id="IEq44"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$u$$\end{document}</tex-math><mml:math id="M4"><mml:mi>u</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq44.gif"/></alternatives></inline-formula> and then selects a node according the weights of vertices in selected hyperedge as the destination vertex <inline-formula id="IEq45"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$v$$\end{document}</tex-math><mml:math id="M6"><mml:mi>v</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq45.gif"/></alternatives></inline-formula> to shift</p></caption><graphic xlink:href="12859_2022_4788_Fig1_HTML" id="MO1"/></fig></p>
    </sec>
    <sec id="Sec4">
      <title>The DriverRWH algorithm</title>
      <p id="Par20">In the present model, mutation data of a given cancer type and a PPI dataset are used as the input information (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>A). As shown in Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>B, a hypergraph consisting of the mutated genes of all samples was constructed. If a gene is mutated in a sample, it would be presented as a vertex in the hyperedge corresponding to the sample. Without loss of generalization, the hypergraph can be defined asÂ <inline-formula id="IEq1"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$HG(V,\mathcal{E})$$\end{document}</tex-math><mml:math id="M8"><mml:mrow><mml:mi>H</mml:mi><mml:mi>G</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>V</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="script">E</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq1.gif"/></alternatives></inline-formula>, where <inline-formula id="IEq2"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$V$$\end{document}</tex-math><mml:math id="M10"><mml:mi>V</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq2.gif"/></alternatives></inline-formula> is the set of vertices and <inline-formula id="IEq3"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\mathcal{E}$$\end{document}</tex-math><mml:math id="M12"><mml:mi mathvariant="script">E</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq3.gif"/></alternatives></inline-formula> is the set of hyperedges. A hyperedge <inline-formula id="IEq4"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$e$$\end{document}</tex-math><mml:math id="M14"><mml:mi>e</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq4.gif"/></alternatives></inline-formula> is a subset of, satisfying <inline-formula id="IEq5"><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\bigcup\limits_{{e \in {\mathcal{E}}}} = V$$\end{document}</tex-math><mml:math id="M16"><mml:mrow><mml:munder><mml:mo movablelimits="false">â</mml:mo><mml:mrow><mml:mi>e</mml:mi><mml:mo>â</mml:mo><mml:mi mathvariant="script">E</mml:mi></mml:mrow></mml:munder><mml:mo>=</mml:mo><mml:mi>V</mml:mi></mml:mrow></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq5.gif"/></alternatives></inline-formula>. Hyperedge <inline-formula id="IEq6"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$e$$\end{document}</tex-math><mml:math id="M18"><mml:mi>e</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq6.gif"/></alternatives></inline-formula> is said to be incident with vertex <inline-formula id="IEq7"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$u$$\end{document}</tex-math><mml:math id="M20"><mml:mi>u</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq7.gif"/></alternatives></inline-formula> ifÂ <inline-formula id="IEq8"><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$u\in e$$\end{document}</tex-math><mml:math id="M22"><mml:mrow><mml:mi>u</mml:mi><mml:mo>â</mml:mo><mml:mi>e</mml:mi></mml:mrow></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq8.gif"/></alternatives></inline-formula>; thus, the incidence matrix <inline-formula id="IEq9"><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$H\in {R}^{|V|\times |\mathcal{E}|}$$\end{document}</tex-math><mml:math id="M24"><mml:mrow><mml:mi>H</mml:mi><mml:mo>â</mml:mo><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mi>V</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mo>Ã</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:mi mathvariant="script">E</mml:mi><mml:mo stretchy="false">|</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq9.gif"/></alternatives></inline-formula> can be defined as follows:<disp-formula id="Equa"><alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$h\left( {u,e} \right) = \left\{ {\begin{array}{*{20}l} 1 \hfill &amp; {{\text{ if }}u \in e} \hfill \\ 0 \hfill &amp; {{\text{ if }}u \notin e} \hfill \\ \end{array} } \right.$$\end{document}</tex-math><mml:math id="M26" display="block"><mml:mrow><mml:mi>h</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi>u</mml:mi><mml:mo>,</mml:mo><mml:mi>e</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfenced open="{"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mn>1</mml:mn></mml:mtd><mml:mtd><mml:mrow><mml:mrow><mml:mspace width="0.333333em"/><mml:mtext>if</mml:mtext><mml:mspace width="0.333333em"/></mml:mrow><mml:mi>u</mml:mi><mml:mo>â</mml:mo><mml:mi>e</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:mrow/><mml:mn>0</mml:mn></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mrow><mml:mspace width="0.333333em"/><mml:mtext>if</mml:mtext><mml:mspace width="0.333333em"/></mml:mrow><mml:mi>u</mml:mi><mml:mo>â</mml:mo><mml:mi>e</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced></mml:mrow></mml:math><graphic xlink:href="12859_2022_4788_Article_Equa.gif" position="anchor"/></alternatives></disp-formula></p>
      <p id="Par21">After construction of the hypergraph, a specified subnetwork is generated for each sample, based on the mutated genes and their interaction in the PPI network. According to our hypothesis that a gene is more likely to be a driver gene if it is highly associated with other mutated genes, a fairly standard choice of the weight of vertices in each hyperedge are their degrees in the corresponding induced subnetwork of the PPI network.</p>
      <p id="Par22">Then, we developed a random walk process on the weighted hypergraph. Similar to a random walk on a simple graph, this walk is a type of Markov process, which is seen as the transition between two vertices. Note that the transition on the hypergraph occurs only if two vertices are incident to a hyperedge, so the random walk on the hypergraph is defined to be a two-step process. In the first step, the surfer selects a hyperedge <inline-formula id="IEq10"><alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$e$$\end{document}</tex-math><mml:math id="M28"><mml:mi>e</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq10.gif"/></alternatives></inline-formula> incident with the current vertex <inline-formula id="IEq11"><alternatives><tex-math id="M29">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$u$$\end{document}</tex-math><mml:math id="M30"><mml:mi>u</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq11.gif"/></alternatives></inline-formula>; thereafter, it selects a target vertex <inline-formula id="IEq12"><alternatives><tex-math id="M31">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$v$$\end{document}</tex-math><mml:math id="M32"><mml:mi>v</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq12.gif"/></alternatives></inline-formula> within the chosen hyperedge (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>C). If one vertex is an isolated node in the subnetwork, it also has the potential to be a driver gene, so a small weight of 0.01 is set. Let <inline-formula id="IEq13"><alternatives><tex-math id="M33">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$Ne$$\end{document}</tex-math><mml:math id="M34"><mml:mrow><mml:mi mathvariant="italic">Ne</mml:mi></mml:mrow></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq13.gif"/></alternatives></inline-formula> be the subnetwork containing vertices in hyperedge <inline-formula id="IEq14"><alternatives><tex-math id="M35">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$e$$\end{document}</tex-math><mml:math id="M36"><mml:mi>e</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq14.gif"/></alternatives></inline-formula> and denote <inline-formula id="IEq15"><alternatives><tex-math id="M37">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{Ne} \left( u \right)$$\end{document}</tex-math><mml:math id="M38"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi mathvariant="italic">Ne</mml:mi></mml:mrow></mml:msub><mml:mfenced close=")" open="("><mml:mi>u</mml:mi></mml:mfenced></mml:mrow></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq15.gif"/></alternatives></inline-formula> as the degree of <inline-formula id="IEq16"><alternatives><tex-math id="M39">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$u$$\end{document}</tex-math><mml:math id="M40"><mml:mi>u</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq16.gif"/></alternatives></inline-formula> in the subnetwork.<disp-formula id="Equb"><alternatives><tex-math id="M41">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$w\left( {u,e} \right) = \left\{ {\begin{array}{*{20}c} {d_{Ne} \left( u \right),} &amp; {{\text{ if }}u \in e} \\ {0.01,} &amp; {{\text{ if }}u \notin e} \\ \end{array} } \right.$$\end{document}</tex-math><mml:math id="M42" display="block"><mml:mrow><mml:mi>w</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi>u</mml:mi><mml:mo>,</mml:mo><mml:mi>e</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfenced open="{"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi mathvariant="italic">Ne</mml:mi></mml:mrow></mml:msub><mml:mfenced close=")" open="("><mml:mi>u</mml:mi></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mrow><mml:mspace width="0.333333em"/><mml:mtext>if</mml:mtext><mml:mspace width="0.333333em"/></mml:mrow><mml:mi>u</mml:mi><mml:mo>â</mml:mo><mml:mi>e</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mrow/><mml:mrow><mml:mn>0.01</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mrow><mml:mspace width="0.333333em"/><mml:mtext>if</mml:mtext><mml:mspace width="0.333333em"/></mml:mrow><mml:mi>u</mml:mi><mml:mo>â</mml:mo><mml:mi>e</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced></mml:mrow></mml:math><graphic xlink:href="12859_2022_4788_Article_Equb.gif" position="anchor"/></alternatives></disp-formula></p>
      <p id="Par23">Thereafter, the surfer selects vertex <inline-formula id="IEq17"><alternatives><tex-math id="M43">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$v$$\end{document}</tex-math><mml:math id="M44"><mml:mi>v</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq17.gif"/></alternatives></inline-formula> proportional to the weight of <inline-formula id="IEq18"><alternatives><tex-math id="M45">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$v$$\end{document}</tex-math><mml:math id="M46"><mml:mi>v</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq18.gif"/></alternatives></inline-formula> within the hyperedge. Notably, in our model, the weights of vertices may vary in accordance with the hyperedges. According to the aforementioned definition, the degree of vertex <inline-formula id="IEq19"><alternatives><tex-math id="M47">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$u$$\end{document}</tex-math><mml:math id="M48"><mml:mi>u</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq19.gif"/></alternatives></inline-formula> and hyperedge <inline-formula id="IEq20"><alternatives><tex-math id="M49">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$e$$\end{document}</tex-math><mml:math id="M50"><mml:mi>e</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq20.gif"/></alternatives></inline-formula> in hypergraph <inline-formula id="IEq21"><alternatives><tex-math id="M51">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$HG\left( {V,{\mathcal{E}}} \right)$$\end{document}</tex-math><mml:math id="M52"><mml:mrow><mml:mi>H</mml:mi><mml:mi>G</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi>V</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="script">E</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq21.gif"/></alternatives></inline-formula> can be defined as follows:<disp-formula id="Equc"><alternatives><tex-math id="M53">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d\left( u \right) = \mathop \sum \limits_{{e \in {\mathcal{E}}}} h\left( {u,e} \right)$$\end{document}</tex-math><mml:math id="M54" display="block"><mml:mrow><mml:mi>d</mml:mi><mml:mfenced close=")" open="("><mml:mi>u</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:munder><mml:mo movablelimits="false">â</mml:mo><mml:mrow><mml:mi>e</mml:mi><mml:mo>â</mml:mo><mml:mi mathvariant="script">E</mml:mi></mml:mrow></mml:munder><mml:mi>h</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi>u</mml:mi><mml:mo>,</mml:mo><mml:mi>e</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:math><graphic xlink:href="12859_2022_4788_Article_Equc.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equd"><alternatives><tex-math id="M55">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${ }\delta \left( e \right) = \mathop \sum \limits_{u \in e} w\left( {u,e} \right)$$\end{document}</tex-math><mml:math id="M56" display="block"><mml:mrow><mml:mrow/><mml:mi>Î´</mml:mi><mml:mfenced close=")" open="("><mml:mi>e</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:munder><mml:mo movablelimits="false">â</mml:mo><mml:mrow><mml:mi>u</mml:mi><mml:mo>â</mml:mo><mml:mi>e</mml:mi></mml:mrow></mml:munder><mml:mi>w</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi>u</mml:mi><mml:mo>,</mml:mo><mml:mi>e</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:math><graphic xlink:href="12859_2022_4788_Article_Equd.gif" position="anchor"/></alternatives></disp-formula></p>
      <p id="Par24">With all the elements defined, we calculated the transition probability from vertex <inline-formula id="IEq22"><alternatives><tex-math id="M57">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$u$$\end{document}</tex-math><mml:math id="M58"><mml:mi>u</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq22.gif"/></alternatives></inline-formula> to vertex <inline-formula id="IEq23"><alternatives><tex-math id="M59">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$v$$\end{document}</tex-math><mml:math id="M60"><mml:mi>v</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq23.gif"/></alternatives></inline-formula> as follows:<disp-formula id="Eque"><alternatives><tex-math id="M61">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$P\left( {u,v} \right) = \mathop \sum \limits_{{e \in {\mathcal{E}}}} \frac{{h\left( {u,e} \right)}}{d\left( u \right)}\frac{{w\left( {v,e} \right)}}{{\mathop \sum \nolimits_{{\hat{v} \in e}} w\left( {\hat{v},e} \right)}}$$\end{document}</tex-math><mml:math id="M62" display="block"><mml:mrow><mml:mi>P</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi>u</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:munder><mml:mo movablelimits="false">â</mml:mo><mml:mrow><mml:mi>e</mml:mi><mml:mo>â</mml:mo><mml:mi mathvariant="script">E</mml:mi></mml:mrow></mml:munder><mml:mfrac><mml:mrow><mml:mi>h</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi>u</mml:mi><mml:mo>,</mml:mo><mml:mi>e</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mfenced close=")" open="("><mml:mi>u</mml:mi></mml:mfenced></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:mi>w</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi>v</mml:mi><mml:mo>,</mml:mo><mml:mi>e</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msub><mml:mo>â</mml:mo><mml:mrow><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>â</mml:mo><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mi>w</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>,</mml:mo><mml:mi>e</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="12859_2022_4788_Article_Eque.gif" position="anchor"/></alternatives></disp-formula></p>
      <p id="Par25">which can also be written in matrix form:<disp-formula id="Equf"><alternatives><tex-math id="M63">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$P = D_{u}^{ - 1} HD_{e}^{ - 1} W^{T}$$\end{document}</tex-math><mml:math id="M64" display="block"><mml:mrow><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>u</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mi>H</mml:mi><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:msup><mml:mi>W</mml:mi><mml:mi>T</mml:mi></mml:msup></mml:mrow></mml:math><graphic xlink:href="12859_2022_4788_Article_Equf.gif" position="anchor"/></alternatives></disp-formula>where <inline-formula id="IEq24"><alternatives><tex-math id="M65">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${D}_{u}\in {R}^{\left|V\right|\times \left|V\right|}$$\end{document}</tex-math><mml:math id="M66"><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mi>u</mml:mi></mml:msub><mml:mo>â</mml:mo><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mfenced close="|" open="|"><mml:mi>V</mml:mi></mml:mfenced><mml:mo>Ã</mml:mo><mml:mfenced close="|" open="|"><mml:mi>V</mml:mi></mml:mfenced></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq24.gif"/></alternatives></inline-formula> is the diagonal vertex degree matrix, <inline-formula id="IEq25"><alternatives><tex-math id="M67">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${D}_{e}\in {R}^{|\mathcal{E}|\times |\mathcal{E}|}$$\end{document}</tex-math><mml:math id="M68"><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:mo>â</mml:mo><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mi mathvariant="script">E</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mo>Ã</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:mi mathvariant="script">E</mml:mi><mml:mo stretchy="false">|</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq25.gif"/></alternatives></inline-formula> is the diagonal hyperedge degree matrix with element <inline-formula id="IEq26"><alternatives><tex-math id="M69">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\delta (e)$$\end{document}</tex-math><mml:math id="M70"><mml:mrow><mml:mi>Î´</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>e</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq26.gif"/></alternatives></inline-formula> and <inline-formula id="IEq27"><alternatives><tex-math id="M71">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$W\in {R}^{|V|\times |\mathcal{E}|}$$\end{document}</tex-math><mml:math id="M72"><mml:mrow><mml:mi>W</mml:mi><mml:mo>â</mml:mo><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mi>V</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mo>Ã</mml:mo><mml:mo stretchy="false">|</mml:mo><mml:mi mathvariant="script">E</mml:mi><mml:mo stretchy="false">|</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq27.gif"/></alternatives></inline-formula> is the weighted incident matrix of hypergraph <inline-formula id="IEq28"><alternatives><tex-math id="M73">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$HG(V,\mathcal{E})$$\end{document}</tex-math><mml:math id="M74"><mml:mrow><mml:mi>H</mml:mi><mml:mi>G</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>V</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="script">E</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq28.gif"/></alternatives></inline-formula>. Note that the transition matrix <inline-formula id="IEq29"><alternatives><tex-math id="M75">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$P$$\end{document}</tex-math><mml:math id="M76"><mml:mi>P</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq29.gif"/></alternatives></inline-formula> is stochastic, where each row sums to 1.</p>
      <p id="Par26">Furthermore, we implemented a random walk with restart on the hypergraph. All genes are considered to be potential driver genes and are assigned with equal probabilities; i.e., the initially normalized probability vector <inline-formula id="IEq30"><alternatives><tex-math id="M77">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\overrightarrow{v}(0)\in {R}^{|V|\times 1}$$\end{document}</tex-math><mml:math id="M78"><mml:mrow><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo stretchy="false">â</mml:mo></mml:mover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>â</mml:mo><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mi>V</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mo>Ã</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq30.gif"/></alternatives></inline-formula> such that each element is assigned with equal probability <inline-formula id="IEq31"><alternatives><tex-math id="M79">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{1}{\left|V\right|}$$\end{document}</tex-math><mml:math id="M80"><mml:mfrac><mml:mn>1</mml:mn><mml:mfenced close="|" open="|"><mml:mi>V</mml:mi></mml:mfenced></mml:mfrac></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq31.gif"/></alternatives></inline-formula>. Moreover, the restart probability at every step is set to be <inline-formula id="IEq32"><alternatives><tex-math id="M81">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$1-\alpha (0&lt;\alpha &lt;1)$$\end{document}</tex-math><mml:math id="M82"><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>Î±</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>&lt;</mml:mo><mml:mi>Î±</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq32.gif"/></alternatives></inline-formula>. In this article, we set <inline-formula id="IEq33"><alternatives><tex-math id="M83">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\alpha$$\end{document}</tex-math><mml:math id="M84"><mml:mi>Î±</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq33.gif"/></alternatives></inline-formula> to be 0.2. Finally, the random walk formula can be expressed as follows:<disp-formula id="Equg"><alternatives><tex-math id="M85">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\vec{v}\left( {t + 1} \right) = \alpha P^{T} \vec{v}\left( t \right) + \left( {1 - \alpha } \right)\vec{v}\left( 0 \right){ },{ }t = 0,1,2, \ldots$$\end{document}</tex-math><mml:math id="M86" display="block"><mml:mrow><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo stretchy="false">â</mml:mo></mml:mover><mml:mfenced close=")" open="("><mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mi>Î±</mml:mi><mml:msup><mml:mi>P</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo stretchy="false">â</mml:mo></mml:mover><mml:mfenced close=")" open="("><mml:mi>t</mml:mi></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>Î±</mml:mi></mml:mrow></mml:mfenced><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo stretchy="false">â</mml:mo></mml:mover><mml:mfenced close=")" open="("><mml:mn>0</mml:mn></mml:mfenced><mml:mrow/><mml:mo>,</mml:mo><mml:mrow/><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mo>â¦</mml:mo></mml:mrow></mml:math><graphic xlink:href="12859_2022_4788_Article_Equg.gif" position="anchor"/></alternatives></disp-formula></p>
      <p id="Par27">In the formula above, <inline-formula id="IEq34"><alternatives><tex-math id="M87">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\overrightarrow{v}(t)$$\end{document}</tex-math><mml:math id="M88"><mml:mrow><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo stretchy="false">â</mml:mo></mml:mover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq34.gif"/></alternatives></inline-formula> is defined such that the <inline-formula id="IEq35"><alternatives><tex-math id="M89">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="M90"><mml:mi>i</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq35.gif"/></alternatives></inline-formula> th element means the probability that the surfer stops at vertex <inline-formula id="IEq36"><alternatives><tex-math id="M91">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="M92"><mml:mi>i</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq36.gif"/></alternatives></inline-formula> at step <inline-formula id="IEq37"><alternatives><tex-math id="M93">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$t$$\end{document}</tex-math><mml:math id="M94"><mml:mi>t</mml:mi></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq37.gif"/></alternatives></inline-formula>. After a number of steps, the random walk will be stable, which can be defined as <inline-formula id="IEq38"><alternatives><tex-math id="M95">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\overrightarrow{v}(\infty )$$\end{document}</tex-math><mml:math id="M96"><mml:mrow><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo stretchy="false">â</mml:mo></mml:mover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>â</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq38.gif"/></alternatives></inline-formula>. The stabilized state implies that the distance between <inline-formula id="IEq39"><alternatives><tex-math id="M97">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\overrightarrow{v}(t+1)$$\end{document}</tex-math><mml:math id="M98"><mml:mrow><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo stretchy="false">â</mml:mo></mml:mover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq39.gif"/></alternatives></inline-formula> and <inline-formula id="IEq40"><alternatives><tex-math id="M99">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\overrightarrow{v}(t)$$\end{document}</tex-math><mml:math id="M100"><mml:mrow><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo stretchy="false">â</mml:mo></mml:mover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq40.gif"/></alternatives></inline-formula> by the L1 norm is smaller than the provided cutoff value. In this paper, we set the cutoff as <inline-formula id="IEq41"><alternatives><tex-math id="M101">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${10}^{-6}$$\end{document}</tex-math><mml:math id="M102"><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>6</mml:mn></mml:mrow></mml:msup></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq41.gif"/></alternatives></inline-formula>. The elements of the stabilized vector <inline-formula id="IEq42"><alternatives><tex-math id="M103">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\overrightarrow{v}$$\end{document}</tex-math><mml:math id="M104"><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo stretchy="false">â</mml:mo></mml:mover></mml:math><inline-graphic xlink:href="12859_2022_4788_Article_IEq42.gif"/></alternatives></inline-formula> are defined as the DriverRWH score, which can reflect the role that the mutated genes play in cancer.</p>
    </sec>
    <sec id="Sec5">
      <title>Datasets and networks</title>
      <p id="Par28">Somatic mutation data for 9183 tumor samples across 31 cancer types (Additional file <xref rid="MOESM2" ref-type="media">2</xref>) used in this work are available from TCGA, which were downloaded by UCSC Browser (<ext-link ext-link-type="uri" xlink:href="https://xenabrowser.net/datapages/">https://xenabrowser.net/datapages/</ext-link>) [<xref ref-type="bibr" rid="CR29">29</xref>]. We downloaded two independently developed PPI datasets from the STRINGv10 (<ext-link ext-link-type="uri" xlink:href="https://string-db.org">https://string-db.org</ext-link>) [<xref ref-type="bibr" rid="CR30">30</xref>] and the HumanNet (<ext-link ext-link-type="uri" xlink:href="http://www.functionalnet.org/humannet/">http://www.functionalnet.org/humannet/</ext-link>) [<xref ref-type="bibr" rid="CR31">31</xref>].</p>
    </sec>
    <sec id="Sec6">
      <title>Performance evaluation</title>
      <p id="Par29">To evaluate the method, an unbiased comprehensive known cancer gene set is needed. Unfortunately, such a gold-standard set of cancer genes is currently unavailable. Alternatively, we used four complementary cancer gene sets derived from various sources as the reference driver gene set for all the cancer types. First, 616 cancer genes were downloaded from the Cancer Gene Census (CGC) database, which includes genes for which mutations have been causally implicated in cancer and is widely used as a gold-standard cancer gene set [<xref ref-type="bibr" rid="CR32">32</xref>]. Second, the list of HiConf cancer gene panels consists of 99 driver genes that have previously been detected through genetic criteria and that could plausibly be detected with exome sequencing data [<xref ref-type="bibr" rid="CR33">33</xref>]. The third set has 291 high-confidence cancer driver genes identified by a rule-based method (HCD) [<xref ref-type="bibr" rid="CR34">34</xref>]. The fourth set contains 125 driver genes defined by the "20/20 rules", which identifies Mut-driver genes based on the characteristic mutational patterns for oncogenes and tumor suppressor genes [<xref ref-type="bibr" rid="CR35">35</xref>]. Now that each cancer gene set is biased toward particular features or study methods, we utilized a union of these four lists as the reference driver gene set, with a total of 785 genes. This operation can reduce the bias caused by using a single reference gene list to some degree. Using aforementioned reference driver genes as a benchmark, we generated receiver operating characteristic (ROC) curves and areas under the curve (AUCs) to evaluate the true positive and false positive rate. For practical reasons, only top-ranked candidate genes might enter into follow-up experimental validation. Considering that the high performance of prioritization for all genes cannot guarantee successful prioritization for the top ranked candidates, we also assessed the number of known driver gene recovered in the top 20, 50, 100,150 and 200 candidate genes.</p>
      <p id="Par30">Due to the diversity of cancer types, we are more interested in tumor-specific drivers than the general common drivers across all tumor types. We downloaded IntOGen database (<ext-link ext-link-type="uri" xlink:href="https://www.intogen.org/download">https://www.intogen.org/download</ext-link>) [<xref ref-type="bibr" rid="CR4">4</xref>]. This database harnesses the strengths of different driver prediction methods and provides a tumor-specific driver genes list, which is considered to be the best trade-off between sensitivity and specificity. This list contains 31 types of cancer among which Kidney Chromophobe (KICH) has 7 specific drivers (minimum) and Uterine Corpus Endometrial Carcinoma (UCEC) has 55 (maximum). All of the above lists are shown in Additional file <xref rid="MOESM3" ref-type="media">3</xref>. From an application point of view, we should assess the ability of our method to identify novel driver genes that may not have been discovered in IntOGen. The genes in top 200 candidate gene list predicted by DriverRWH with both HumanNet and STRINGv10 while not in the tumor-specific drivers were considered to be potential novel drivers. From the functional perspective, these genes were evaluated by the biological analysis using DAVID on-line database, CancerGeneNet and iGMDR database [<xref ref-type="bibr" rid="CR36">36</xref>â<xref ref-type="bibr" rid="CR39">39</xref>].</p>
      <p id="Par31">We leveraged a literature mining method named CoCiter, which calculates the co-citation significance between predicted driver genes and the keywords cancer type, âdriverâ and âcancerâ to verify the top 30 significant genes [<xref ref-type="bibr" rid="CR40">40</xref>]. The higher co-citation score implicates the stronger association between the genes and the key terms. Without loss of generality, we compared DriverRWH with 24 driver gene prediction methods across 31 cancer type, some of which identify significant drivers by <italic>P</italic>-value (the genes with FDR adjusted <italic>P</italic>-valueâ&lt;â0.05) and the rest of methods provide the priority scores for candidate driver genes (the top 30 genes are selected as significant drivers). It is acceptable for the reason that the median number of significant genes for other methods in all data sets is 30.</p>
    </sec>
  </sec>
  <sec id="Sec7">
    <title>Results</title>
    <sec id="Sec8">
      <title>Known driver genes have higher degree in the PPI network</title>
      <p id="Par32">In DriverRWH, we hypothesized that a gene is more likely to be a cancer driver if it is prone to associate with other mutated genes in cancer. This hypothesis has already been proposed in some studies [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. To further validate it, we analyzed the linkage of mutated genes in the PPI network. For a given cancer type, an induced subnetwork of the PPI network which just contains mutated genes from all samples was built. The genes that mutated at least once in a cancer type were divided into two groups according to whether they are in the reference driver gene set (the union of CGC, HiConf, MCD, Mut-driver, with a total number of 785 genes): known driver genes and the others. We calculated the degree of vertices in the induced subnetwork. Taking the three cancer types LUSC, BRCA and UCEC for illustration, we found the degrees of known driver genes were significantly larger than those of the other mutant genes (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>, <italic>P</italic>-valueâ&lt;â0.001). This result suggests that cancer driver genes were adjacent to more mutated genes than the others. The same analysis using HumanNet is also available (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig S1).<fig id="Fig2"><label>Fig. 2</label><caption><p>Boxplot comparing the degrees of known driver and the other genes in induced subnetwork. Bracketed digits indicate the number of known driver genes and the other genes in the subnetwork of STRINGv10, which are induced by the mutated genes present in at least one tumor sample for a given cancer type</p></caption><graphic xlink:href="12859_2022_4788_Fig2_HTML" id="MO2"/></fig></p>
    </sec>
    <sec id="Sec9">
      <title>Performance of DriverRWH</title>
      <p id="Par33">To evaluate the performance of our method, we compared our method from three aspects, prediction of known driver genes, functional enrichment analysis and literature mining analysis. Firstly, we implemented six prioritizing methods, MutsigCV [<xref ref-type="bibr" rid="CR8">8</xref>], DawnRank [<xref ref-type="bibr" rid="CR14">14</xref>], MinNetRank [<xref ref-type="bibr" rid="CR16">16</xref>], Subdyquency [<xref ref-type="bibr" rid="CR17">17</xref>], Gravity [<xref ref-type="bibr" rid="CR41">41</xref>] and OncodriveFML [<xref ref-type="bibr" rid="CR42">42</xref>] on three cancer types, namely Lung squamous cell carcinoma (LUSC), Breast invasive carcinoma (BRCA), and Uterine Corpus Endometrial Carcinoma (UCEC) (see Additional file <xref rid="MOESM4" ref-type="media">4</xref>). In order to eliminate the deviation brought by the background network, we operated DriverRWH and the other three network-based methods (MinNetRank, Subdyquency, and Dawnrank) basing on the same network, STRINGv10 and HumanNet respectively. Then, we compared DriverRWH with 24 other driver gene prediction tools to evaluated its performance across 31 cancer types. Lastly, we verified the robustness of our method by testing the performance in perturbed data where the mutation data and network data were extracted randomly with different size.</p>
      <sec id="Sec10">
        <title>Results for lung squamous cell carcinoma</title>
        <p id="Par34">Lung cancer is regarded as the main leading cause of cancer deaths, which take up 18.0% of deaths [<xref ref-type="bibr" rid="CR43">43</xref>]. In this research, we applied DriverRWH to 480 LUSC samples in TCGA database.</p>
        <p id="Par35">Using reference driver genes as benchmarks, we generated receiver operating characteristic (ROC) curves. When using STRINGv10 as background network, DriverRWH outperforms the other six tools. in terms of sensitivity and specificity in identifying known driver gene (Fig.Â <xref rid="Fig3" ref-type="fig">3</xref>A). We further assessed the predictive power for the top-ranked candidate genes. As shown in Fig.Â <xref rid="Fig3" ref-type="fig">3</xref>B, we observed that DriverRWH identified more known cancer driver genes by its top 20, 50, 100, 150 and 200 genes. Furthermore, the number of know driver gene retrieved by DriverRWH with STRINGv10 network in its 20 top-ranked candidates is more than half of it. When HumanNet was used, DriverRWH is still significantly better than the others methods (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig S2).<fig id="Fig3"><label>Fig. 3</label><caption><p>Prediction performance of DriverRWH based on the reference driver set. <bold>A</bold> ROC plots of DriverRWH and other six methods. All the network-based methods, DriverRWH, Subdyquency, MinNetRank and Dawnrank were implemented by using STRINGv10 as background network. <bold>B</bold> Cumulative number of known cancer genes recovered within the top 20, 50, 100, 150 and 200</p></caption><graphic xlink:href="12859_2022_4788_Fig3_HTML" id="MO3"/></fig></p>
        <p id="Par36">To assess the ability of DriverRWH of discovering potential novel cancer driver genes, we considered the genes in the 200 top ranked candidate genes predicted with both HumanNet and the STRINGv10 while not in tumor-specific drivers list, resulting in 72 genes after screening. Biological enrichment analysis using DAVID against Genetic Association Database (GAD) shows that 36 genes (48.6%) are cancer-related (<italic>P</italic>-valueâ=â5.92âÃâ10<sup>â6</sup>, FDRâ=â5.92âÃâ10<sup>â4</sup>) [<xref ref-type="bibr" rid="CR44">44</xref>]. In particular, these genes are enriched for "lung cancer" (<italic>P</italic>-valueâ=â1âÃâ10<sup>â3</sup>, FDRâ=â0.1217). Furthermore, the KEGG pathway enrichment analysis for the potential drivers is encouraging. 8 genes (11.2%) are significantly enriched in pathway: "PI3Kâ-âAkt signaling pathway" (<italic>P</italic>-adjustâ&lt;â0.05), which is significantly related to lung cancer (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig S3) [<xref ref-type="bibr" rid="CR45">45</xref>â<xref ref-type="bibr" rid="CR48">48</xref>].</p>
        <p id="Par37">Specifically, using the top 30 candidate genes as significant driver, we searched these genes in co-citer website by the key terms âCancerâ, âDriverâ and âLungâ. As Table <xref rid="Tab1" ref-type="table">1</xref> shows, some significant well-known driver genes like TP53, PTEN and PIK3CA are near the top of the list. Although they are also identified by most of other methods, their ranking fell behind ours. The well-known suppressor TP53 which disrupts the cell cycle arrest and the apoptosis pathways in human cancer ranks first in our method, but it ranks 527th in Gravity algorithm. The PTEN is proved to be related to small cell lung cancer, which is an admitted tumor suppressor gene with phosphatase activity [<xref ref-type="bibr" rid="CR49">49</xref>]. It is co-cited with âLungâ and âCancerâ for 253 and 2597 times, which is regarded as driver genes in 35 publications. The PTEN ranks the 16th in our list but ranked 44th in MinNetRank and 588th in Gravity. The mutation of PIK3CA gene can lead to abnormal enhancement of the catalytic activity of PI3Ks and promote the carcinogenesis of cells in lung cancer [<xref ref-type="bibr" rid="CR49">49</xref>]. It ranks 7th in our method but 22th in MutsigCV and OncodriveFML, and 473th in MinNetRank. On the other hand, KDR (Kinase insert domain-containing receptor), ranked 24th, was reported to play a critical role in the metastasis of cancer and is used as a molecular target in cancer therapy [<xref ref-type="bibr" rid="CR50">50</xref>]. Co-cited with "Cancer" for 207 times and âLungâ for 105 times, KDR even not deemed as a diver gene in lung cancer and can be thought as a potential driver. The similar analysis basing on HumanNet is also available (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Cociter mining analysis of top 30 LUSC candidate driver genes identified by DriverRWH (STRINGv10)</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="left" rowspan="2">Genes</th><th align="left" colspan="3">Co-appeared count</th><th valign="middle" align="left" rowspan="2">Is_Specificity</th><th align="left" colspan="6">Rank position</th></tr><tr><th align="left">Lung</th><th align="left">Cancer</th><th align="left">Driver</th><th align="left">MutsigCV</th><th align="left">Dawnrank</th><th align="left">Gravity</th><th align="left">OncodriveFML</th><th align="left">Subdyquency</th><th align="left">MinNetRank</th></tr></thead><tbody><tr><td align="left">TP53</td><td align="left">854</td><td align="left">5942</td><td align="left">55</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">527</td><td align="left">3</td><td align="left">1</td><td align="left">3</td></tr><tr><td align="left">TTN</td><td align="left">1</td><td align="left">8</td><td align="left">1</td><td align="left">0</td><td align="left">2</td><td align="left">2771</td><td align="left">3959</td><td align="left">13,175</td><td align="left">NA</td><td align="left">1424</td></tr><tr><td align="left">DNAH8</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">15</td><td align="left">2</td><td align="left">NA</td><td align="left">2741</td><td align="left">3</td><td align="left">73</td></tr><tr><td align="left">RYR2</td><td align="left">3</td><td align="left">3</td><td align="left">2</td><td align="left">0</td><td align="left">4</td><td align="left">492</td><td align="left">400</td><td align="left">11,456</td><td align="left">2</td><td align="left">1706</td></tr><tr><td align="left">LRRK2</td><td align="left">5</td><td align="left">18</td><td align="left">1</td><td align="left">0</td><td align="left">58</td><td align="left">3</td><td align="left">1556</td><td align="left">10,604</td><td align="left">NA</td><td align="left">223</td></tr><tr><td align="left">PTEN</td><td align="left">253</td><td align="left">2597</td><td align="left">35</td><td align="left">1</td><td align="left">26</td><td align="left">6</td><td align="left">588</td><td align="left">2</td><td align="left">14</td><td align="left">44</td></tr><tr><td align="left">PIK3CA</td><td align="left">94</td><td align="left">576</td><td align="left">13</td><td align="left">1</td><td align="left">22</td><td align="left">36</td><td align="left">2536</td><td align="left">22</td><td align="left">11</td><td align="left">473</td></tr><tr><td align="left">NOTCH1</td><td align="left">84</td><td align="left">486</td><td align="left">23</td><td align="left">1</td><td align="left">49</td><td align="left">24</td><td align="left">1591</td><td align="left">20</td><td align="left">18</td><td align="left">47</td></tr><tr><td align="left">CSMD3</td><td align="left">0</td><td align="left">3</td><td align="left">1</td><td align="left">0</td><td align="left">3</td><td align="left">2434</td><td align="left">NA</td><td align="left">46</td><td align="left">NA</td><td align="left">940</td></tr><tr><td align="left">ANK2</td><td align="left">1</td><td align="left">4</td><td align="left">0</td><td align="left">0</td><td align="left">99</td><td align="left">675</td><td align="left">576</td><td align="left">13,775</td><td align="left">NA</td><td align="left">4868</td></tr><tr><td align="left">SYNE1</td><td align="left">1</td><td align="left">2</td><td align="left">1</td><td align="left">0</td><td align="left">11</td><td align="left">4</td><td align="left">181</td><td align="left">4035</td><td align="left">NA</td><td align="left">8653</td></tr><tr><td align="left">KMT2D</td><td align="left">1</td><td align="left">18</td><td align="left">1</td><td align="left">1</td><td align="left">NA</td><td align="left">NA</td><td align="left">3147</td><td align="left">1</td><td align="left">NA</td><td align="left">8656</td></tr><tr><td align="left">DMD</td><td align="left">14</td><td align="left">19</td><td align="left">3</td><td align="left">0</td><td align="left">23</td><td align="left">419</td><td align="left">1998</td><td align="left">11,399</td><td align="left">NA</td><td align="left">566</td></tr><tr><td align="left">USH2A</td><td align="left">2</td><td align="left">4</td><td align="left">1</td><td align="left">0</td><td align="left">6</td><td align="left">1136</td><td align="left">4591</td><td align="left">13,959</td><td align="left">NA</td><td align="left">215</td></tr><tr><td align="left">OBSCN</td><td align="left">0</td><td align="left">4</td><td align="left">0</td><td align="left">0</td><td align="left">209</td><td align="left">2458</td><td align="left">204</td><td align="left">9252</td><td align="left">NA</td><td align="left">1487</td></tr><tr><td align="left">RYR1</td><td align="left">0</td><td align="left">3</td><td align="left">1</td><td align="left">0</td><td align="left">53</td><td align="left">64</td><td align="left">1788</td><td align="left">1299</td><td align="left">4</td><td align="left">590</td></tr><tr><td align="left">NF1</td><td align="left">12</td><td align="left">137</td><td align="left">8</td><td align="left">1</td><td align="left">52</td><td align="left">2179</td><td align="left">3255</td><td align="left">2881</td><td align="left">13</td><td align="left">1106</td></tr><tr><td align="left">LRP1B</td><td align="left">8</td><td align="left">15</td><td align="left">2</td><td align="left">0</td><td align="left">5</td><td align="left">2397</td><td align="left">399</td><td align="left">9317</td><td align="left">NA</td><td align="left">1471</td></tr><tr><td align="left">APOB</td><td align="left">3</td><td align="left">23</td><td align="left">1</td><td align="left">0</td><td align="left">84</td><td align="left">388</td><td align="left">253</td><td align="left">8676</td><td align="left">NA</td><td align="left">1465</td></tr><tr><td align="left">RELN</td><td align="left">0</td><td align="left">9</td><td align="left">2</td><td align="left">0</td><td align="left">113</td><td align="left">172</td><td align="left">40</td><td align="left">13,119</td><td align="left">NA</td><td align="left">3089</td></tr><tr><td align="left">MYH1</td><td align="left">1</td><td align="left">14</td><td align="left">1</td><td align="left">0</td><td align="left">122</td><td align="left">630</td><td align="left">NA</td><td align="left">6933</td><td align="left">NA</td><td align="left">2615</td></tr><tr><td align="left">EPHA5</td><td align="left">2</td><td align="left">6</td><td align="left">1</td><td align="left">0</td><td align="left">172</td><td align="left">8</td><td align="left">NA</td><td align="left">7697</td><td align="left">28</td><td align="left">90</td></tr><tr><td align="left">MYH2</td><td align="left">4</td><td align="left">3</td><td align="left">1</td><td align="left">0</td><td align="left">44</td><td align="left">98</td><td align="left">NA</td><td align="left">5025</td><td align="left">7</td><td align="left">2538</td></tr><tr><td align="left">KDR</td><td align="left">105</td><td align="left">207</td><td align="left">3</td><td align="left">0</td><td align="left">131</td><td align="left">22</td><td align="left">549</td><td align="left">2832</td><td align="left">71</td><td align="left">43</td></tr><tr><td align="left">HERC2</td><td align="left">0</td><td align="left">14</td><td align="left">1</td><td align="left">0</td><td align="left">155</td><td align="left">5624</td><td align="left">148</td><td align="left">8436</td><td align="left">15</td><td align="left">2403</td></tr><tr><td align="left">POTEE</td><td align="left">1</td><td align="left">9</td><td align="left">0</td><td align="left">0</td><td align="left">1153</td><td align="left">40</td><td align="left">3138</td><td align="left">8733</td><td align="left">67</td><td align="left">229</td></tr><tr><td align="left">PIK3CG</td><td align="left">36</td><td align="left">119</td><td align="left">1</td><td align="left">0</td><td align="left">426</td><td align="left">21</td><td align="left">602</td><td align="left">8186</td><td align="left">51</td><td align="left">234</td></tr><tr><td align="left">CPS1</td><td align="left">2</td><td align="left">6</td><td align="left">1</td><td align="left">0</td><td align="left">71</td><td align="left">5</td><td align="left">3852</td><td align="left">13,518</td><td align="left">NA</td><td align="left">387</td></tr><tr><td align="left">KMT2C</td><td align="left">3</td><td align="left">21</td><td align="left">4</td><td align="left">1</td><td align="left">NA</td><td align="left">NA</td><td align="left">5041</td><td align="left">479</td><td align="left">NA</td><td align="left">4264</td></tr><tr><td align="left">HDAC9</td><td align="left">5</td><td align="left">18</td><td align="left">1</td><td align="left">0</td><td align="left">371</td><td align="left">1640</td><td align="left">3783</td><td align="left">10,894</td><td align="left">85</td><td align="left">944</td></tr></tbody></table></table-wrap></p>
        <p id="Par38">We adopted the GAD and KEGG pathway enrichment analysis and found these significant driver genes enrich in the small cell lung cancer, PI3K-Akt signaling pathway, etc., which are significantly related to lung cancer (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig S3). The hallmarks of cancer are defined as a set of crucial functional abilities acquired by human cells as they move from normalcy to neoplastic growth states [<xref ref-type="bibr" rid="CR51">51</xref>]. We linked these significant drivers to hallmarks of cancer using CancerGeneNet online database which calculates the shortest paths between genes and phenotypes [<xref ref-type="bibr" rid="CR38">38</xref>]. Half of the top 30 genes could be associated with hallmarks of cancer. KDR, one of the potential drivers we mentioned above, is linked to âAngiogenesisâ, âCell Deathâ, âDifferentiationâ, âDNA Repairâ, âGlycolysisâ, âImmortalityâ, âInflammationâ, âMetastasisâ and âProliferationâ (Additional file <xref rid="MOESM5" ref-type="media">5</xref>). In order to assess the drug sensitivity of these significant drivers, we performed gene-drug analysis using online database iGMDR, which shows that 73.3% of significant genes are druggable (Additional file <xref rid="MOESM6" ref-type="media">6</xref>).</p>
      </sec>
      <sec id="Sec11">
        <title>Results for breast invasive carcinoma</title>
        <p id="Par39">Breast cancer is the most commonly diagnosed cancer, with an estimate 2.3 million new cases, taking up to 11.7% of all the cancer cases in 2020 [<xref ref-type="bibr" rid="CR43">43</xref>]. We focused on 791 BRCA samples in TCGA database to construct the hypergraph.</p>
        <p id="Par40">Compared with other methods, DriverRWH shows the best performance in terms of ROC curves when STRINGv10 and HumanNet were used respectively (Fig.Â <xref rid="Fig4" ref-type="fig">4</xref> and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig S4). Meanwhile, although DriverRWH discerned less driver gene than MutSigCV in top 20 candidates, it was found to predict more known driver genes in the top 50, 100, 150 and 200 candidates (Fig.Â <xref rid="Fig4" ref-type="fig">4</xref>B). <fig id="Fig4"><label>Fig. 4</label><caption><p>Prediction performance of DriverRWH based on the reference driver set. <bold>A</bold> ROC plots of DriverRWH and other six methods. All the network-based methods, DriverRWH, Subdyquency, MinNetRank and Dawnrank were implemented by using STRINGv10 as background network. <bold>B</bold> Cumulative number of known cancer genes recovered within the top 20, 50, 100, 150 and 200</p></caption><graphic xlink:href="12859_2022_4788_Fig4_HTML" id="MO4"/></fig></p>
        <p id="Par41">We evaluated the capacity of DriverRWH in identifying the breast cancer potential driver genes. Similarly, we adopted 61 genes, which are in the 200 top ranked candidate genes predicted with both HumanNet and the STRINGv10 while not in tumor-specific drivers list to conduct the GAD and pathway enrichment analysis. Notably, 29 genes (44.6%) are enriched for "CANCER" (<italic>P</italic>-valueâ=â1.67âÃâ10<sup>â4</sup>, FDRâ=â1.67âÃâ10<sup>â4</sup>) and 12 (18.5%) are enriched for "breast cancer" (<italic>P</italic>-valueâ=â2.15âÃâ10<sup>â5</sup>, FDRâ=â0.0087). In the case of pathways, these genes are significantly enriched in "Breast cancer". The top 25 pathways are shown in additional file (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig S5).</p>
        <p id="Par42">The cociter score of the top 30 candidate genes predicted by DriverRWH using STRINGv10 network is demonstrated in Table <xref rid="Tab2" ref-type="table">2</xref>. Particularly, 8 of the top 10 candidate genes are exactly driver genes, including acknowledged driver gene TP53 (ranked 1st), the most recurrently mutated gene PIK3CA (ranked second), etc. With high cociter scores, KMT2C ranked 8th in DriverRWH, not even identified in MutsigCV and Dawnrank and ranked 2121 in Gravity. AKT1, which co-appears with "Cancer" for 1863 times and "Breast" for 477 times, ranked 10th in DriverRWH while it ranked merely 1226th in Gravity and 2233th in OncodriveFML. The ERBB2, which ranked 16th in DriverRWH, is confirmed to be related to breast cancer, but it ranked 35th in OncodriveFML, 126th in MutsigCV, and even 1465th in Gravity [<xref ref-type="bibr" rid="CR52">52</xref>]. Besides, DriverRWH can identify some genes that are highly related with breast cancer but was not recognized by other six methods. For instance, EGFR is one of the first identified important targets of novel antitumor agents, which co-occur "Breast" 722 times, "Cancer" 4091 times, and "Driver" 94 times [<xref ref-type="bibr" rid="CR53">53</xref>]. MTOR ranked 22nd, co-appearing 321 times with "Breast", 1896 times with "Cancer", and 21 times with "Driver". The similar analysis basing on HumanNet is also available (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Cociter mining analysis of top 30 BRCA candidate driver genes identified by DriverRWH (STRINGv10)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Genes</th><th align="left" colspan="3">Co-appeared count</th><th align="left" rowspan="2">Is_Specificity</th><th align="left" colspan="6">Rank position</th></tr><tr><th align="left">Breast</th><th align="left">Cancer</th><th align="left">Driver</th><th align="left">MutsigCV</th><th align="left">Dawnrank</th><th align="left">Gravity</th><th align="left">OncodriveFML</th><th align="left">Subdyquency</th><th align="left">MinNetRank</th></tr></thead><tbody><tr><td align="left">TP53</td><td align="left">1177</td><td align="left">5942</td><td align="left">55</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">884</td><td align="left">5</td><td align="left">2</td><td align="left">24</td></tr><tr><td align="left">PIK3CA</td><td align="left">170</td><td align="left">576</td><td align="left">13</td><td align="left">1</td><td align="left">2</td><td align="left">4</td><td align="left">3949</td><td align="left">9885</td><td align="left">1</td><td align="left">200</td></tr><tr><td align="left">CDH1</td><td align="left">291</td><td align="left">1143</td><td align="left">13</td><td align="left">1</td><td align="left">3</td><td align="left">2</td><td align="left">448</td><td align="left">6</td><td align="left">4</td><td align="left">52</td></tr><tr><td align="left">GATA3</td><td align="left">84</td><td align="left">114</td><td align="left">4</td><td align="left">1</td><td align="left">4</td><td align="left">11</td><td align="left">179</td><td align="left">1</td><td align="left">NA</td><td align="left">8652</td></tr><tr><td align="left">TTN</td><td align="left">2</td><td align="left">8</td><td align="left">1</td><td align="left">0</td><td align="left">NA</td><td align="left">3148</td><td align="left">197</td><td align="left">16,438</td><td align="left">3</td><td align="left">6097</td></tr><tr><td align="left">PTEN</td><td align="left">595</td><td align="left">2597</td><td align="left">35</td><td align="left">1</td><td align="left">6</td><td align="left">3</td><td align="left">300</td><td align="left">7</td><td align="left">10</td><td align="left">42</td></tr><tr><td align="left">MAP3K1</td><td align="left">59</td><td align="left">129</td><td align="left">2</td><td align="left">1</td><td align="left">5</td><td align="left">122</td><td align="left">208</td><td align="left">4</td><td align="left">5</td><td align="left">528</td></tr><tr><td align="left">KMT2C</td><td align="left">3</td><td align="left">21</td><td align="left">4</td><td align="left">1</td><td align="left">NA</td><td align="left">NA</td><td align="left">2121</td><td align="left">3</td><td align="left">NA</td><td align="left">4076</td></tr><tr><td align="left">DNAH8</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">115</td><td align="left">7</td><td align="left">NA</td><td align="left">1942</td><td align="left">78</td><td align="left">122</td></tr><tr><td align="left">AKT1</td><td align="left">477</td><td align="left">1863</td><td align="left">13</td><td align="left">1</td><td align="left">NA</td><td align="left">6</td><td align="left">1226</td><td align="left">2233</td><td align="left">NA</td><td align="left">31</td></tr><tr><td align="left">OBSCN</td><td align="left">1</td><td align="left">4</td><td align="left">0</td><td align="left">0</td><td align="left">NA</td><td align="left">1724</td><td align="left">642</td><td align="left">15,684</td><td align="left">14</td><td align="left">1760</td></tr><tr><td align="left">DMD</td><td align="left">1</td><td align="left">19</td><td align="left">3</td><td align="left">0</td><td align="left">16</td><td align="left">17</td><td align="left">1457</td><td align="left">5795</td><td align="left">11</td><td align="left">827</td></tr><tr><td align="left">NF1</td><td align="left">19</td><td align="left">137</td><td align="left">8</td><td align="left">1</td><td align="left">13</td><td align="left">998</td><td align="left">1641</td><td align="left">25</td><td align="left">34</td><td align="left">926</td></tr><tr><td align="left">UBC</td><td align="left">176</td><td align="left">653</td><td align="left">4</td><td align="left">0</td><td align="left">197</td><td align="left">29</td><td align="left">NA</td><td align="left">2704</td><td align="left">38</td><td align="left">16</td></tr><tr><td align="left">PRDM10</td><td align="left">1</td><td align="left">1</td><td align="left">2</td><td align="left">0</td><td align="left">916</td><td align="left">21</td><td align="left">4104</td><td align="left">49</td><td align="left">560</td><td align="left">27</td></tr><tr><td align="left">ERBB2</td><td align="left">3631</td><td align="left">4422</td><td align="left">36</td><td align="left">1</td><td align="left">126</td><td align="left">5</td><td align="left">1465</td><td align="left">35</td><td align="left">33</td><td align="left">51</td></tr><tr><td align="left">MYH9</td><td align="left">10</td><td align="left">32</td><td align="left">4</td><td align="left">0</td><td align="left">30</td><td align="left">358</td><td align="left">1540</td><td align="left">4141</td><td align="left">NA</td><td align="left">476</td></tr><tr><td align="left">NCOR1</td><td align="left">16</td><td align="left">58</td><td align="left">2</td><td align="left">1</td><td align="left">9</td><td align="left">2903</td><td align="left">76</td><td align="left">22</td><td align="left">7</td><td align="left">3160</td></tr><tr><td align="left">FOXA1</td><td align="left">82</td><td align="left">128</td><td align="left">5</td><td align="left">1</td><td align="left">26</td><td align="left">26</td><td align="left">33</td><td align="left">21</td><td align="left">NA</td><td align="left">8660</td></tr><tr><td align="left">ANK3</td><td align="left">3</td><td align="left">4</td><td align="left">2</td><td align="left">0</td><td align="left">NA</td><td align="left">3251</td><td align="left">2415</td><td align="left">4803</td><td align="left">54</td><td align="left">2288</td></tr><tr><td align="left">LRRK2</td><td align="left">4</td><td align="left">18</td><td align="left">1</td><td align="left">0</td><td align="left">218</td><td align="left">39</td><td align="left">7388</td><td align="left">3480</td><td align="left">278</td><td align="left">270</td></tr><tr><td align="left">MTOR</td><td align="left">321</td><td align="left">1896</td><td align="left">21</td><td align="left">0</td><td align="left">NA</td><td align="left">22</td><td align="left">664</td><td align="left">1419</td><td align="left">47</td><td align="left">115</td></tr><tr><td align="left">EGFR</td><td align="left">722</td><td align="left">4091</td><td align="left">94</td><td align="left">0</td><td align="left">NA</td><td align="left">10</td><td align="left">2909</td><td align="left">14,413</td><td align="left">1195</td><td align="left">35</td></tr><tr><td align="left">RYR2</td><td align="left">2</td><td align="left">3</td><td align="left">2</td><td align="left">0</td><td align="left">NA</td><td align="left">1689</td><td align="left">2525</td><td align="left">12,929</td><td align="left">9</td><td align="left">2197</td></tr><tr><td align="left">PRKDC</td><td align="left">57</td><td align="left">274</td><td align="left">4</td><td align="left">0</td><td align="left">77</td><td align="left">12</td><td align="left">127</td><td align="left">9326</td><td align="left">51</td><td align="left">312</td></tr><tr><td align="left">ANK2</td><td align="left">0</td><td align="left">4</td><td align="left">0</td><td align="left">0</td><td align="left">NA</td><td align="left">405</td><td align="left">3532</td><td align="left">971</td><td align="left">44</td><td align="left">4349</td></tr><tr><td align="left">ASH1L</td><td align="left">0</td><td align="left">2</td><td align="left">1</td><td align="left">0</td><td align="left">109</td><td align="left">5672</td><td align="left">957</td><td align="left">6540</td><td align="left">85</td><td align="left">2723</td></tr><tr><td align="left">KDM6A</td><td align="left">5</td><td align="left">24</td><td align="left">3</td><td align="left">0</td><td align="left">64</td><td align="left">5042</td><td align="left">2140</td><td align="left">78</td><td align="left">NA</td><td align="left">2380</td></tr><tr><td align="left">SYNE1</td><td align="left">0</td><td align="left">2</td><td align="left">1</td><td align="left">0</td><td align="left">NA</td><td align="left">1801</td><td align="left">1233</td><td align="left">12,287</td><td align="left">NA</td><td align="left">8654</td></tr><tr><td align="left">RUNX1</td><td align="left">14</td><td align="left">110</td><td align="left">6</td><td align="left">1</td><td align="left">7</td><td align="left">2058</td><td align="left">748</td><td align="left">17</td><td align="left">28</td><td align="left">3175</td></tr></tbody></table></table-wrap></p>
        <p id="Par43">We performed GAD and pathway enrichment analysis of the top 30 candidate driver genes. The identified genes are enriched in "breast cancer" in GAD. These gene are significantly enriched in "Breast cancer", "Proteoglycans in cancer", "Endometrial cancer", etc., which have an association with breast cancer by KEGG enrichment analysis (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig S5). 66.7% of the candidate driver genes could be linked to hallmarks of cancer (Additional file <xref rid="MOESM5" ref-type="media">5</xref>). Besides, 86.7% of the identified genes are druggable according to the iGMDR database (Additional file <xref rid="MOESM6" ref-type="media">6</xref>).</p>
      </sec>
      <sec id="Sec12">
        <title>Results for uterine corpus cancer</title>
        <p id="Par44">Uterine corpus cancer is the sixth most common type of cancer and the second most common gynecological malignancy in female, with more than 417,000 new cases and 97,000 deaths worldwide in 2020 [<xref ref-type="bibr" rid="CR54">54</xref>]. We used 448 patients with 40,543 candidate genes from the TCGA database.</p>
        <p id="Par45">DriverRWH outperforms the other six prioritizing methods with the same reference driver genes as benchmarks when assessed by the ROC and percentage of known driver gene in the top candidate genes (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref> and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig S6).<fig id="Fig5"><label>Fig. 5</label><caption><p>Prediction performance of DriverRWH based on the reference driver set. <bold>A</bold> ROC plots of DriverRWH and other six methods. All the network-based methods, DriverRWH, Subdyquency, MinNetRank and Dawnrank were implemented by using STRINGv10 as background network. <bold>B</bold> Cumulative number of known cancer genes recovered within the top 20, 50, 100, 150 and 200</p></caption><graphic xlink:href="12859_2022_4788_Fig5_HTML" id="MO5"/></fig></p>
        <p id="Par46">For the discovery of potential drives, we selected 41 genes with the same criteria mentioned earlier, of which 22 genes (51.2%) are association with cancer (<italic>P</italic>-valueâ=â1.37âÃâ10<sup>â4</sup>, FDRâ=â1.37âÃâ10<sup>â4</sup>). These genes are significantly enriched in PI3Kâ-âAkt signaling pathway and MAPK signaling pathway, both of which play an important role in cellular growth and survival, have been implicated in endometrial cancer pathogenesis (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig S7) [<xref ref-type="bibr" rid="CR55">55</xref>]. </p>
        <p id="Par47">We took top 30 candidate drivers in consideration, Table <xref rid="Tab3" ref-type="table">3</xref> shows the cociter score between these candidate genes and the terms " Endometrial", "Cancer" and "Drivers". Apoptosis-suppressing gene MTOR which co-appears with "Endometrial" 63 times, with "Cancer" 1896 times, ranked 19th in DriverRWH, but ranked 112th, 182th, and 1380th in Dawnrank, MutsigCV and OncodriveFML. Notch1 is tumor-suppressive in human endometrial cancer cells [<xref ref-type="bibr" rid="CR56">56</xref>], which ranked 11th in DriverRWH, while 61th in MutsigCV, 94th in Subdyquency, even 2630th in OncodriveFML and 7054th in Gravity. Moreover, PRKDC is proved to be significantly associated with a high mutation load, which ranked 20th in DriverRWH [<xref ref-type="bibr" rid="CR57">57</xref>]. Recent research suggest that high mutation load is a predictive biomarker of response to immune checkpoint inhibitors in uterine corpus cancer [<xref ref-type="bibr" rid="CR58">58</xref>]. The similar analysis basing on HumanNet is also available (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S3).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Cociter mining analysis of top 30 UCEC candidate driver genes identified by DriverRWH (STRINGv10)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Genes</th><th align="left" colspan="3">Co-appeared count</th><th align="left" rowspan="2">Is_Specificity</th><th align="left" colspan="6">Rank position</th></tr><tr><th align="left">Endometrial</th><th align="left">Cancer</th><th align="left">Driver</th><th align="left">MutsigCV</th><th align="left">Dawnrank</th><th align="left">Gravity</th><th align="left">OncodriveFML</th><th align="left">Subdyquency</th><th align="left">MinNetRank</th></tr></thead><tbody><tr><td align="left">PTEN</td><td align="left">380</td><td align="left">2597</td><td align="left">35</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">233</td><td align="left">168</td><td align="left">1</td><td align="left">9</td></tr><tr><td align="left">TP53</td><td align="left">143</td><td align="left">5942</td><td align="left">55</td><td align="left">1</td><td align="left">2</td><td align="left">2</td><td align="left">1687</td><td align="left">403</td><td align="left">4</td><td align="left">43</td></tr><tr><td align="left">PIK3CA</td><td align="left">39</td><td align="left">576</td><td align="left">13</td><td align="left">1</td><td align="left">3</td><td align="left">34</td><td align="left">2</td><td align="left">673</td><td align="left">2</td><td align="left">73</td></tr><tr><td align="left">CTNNB1</td><td align="left">112</td><td align="left">2014</td><td align="left">29</td><td align="left">1</td><td align="left">5</td><td align="left">5</td><td align="left">10</td><td align="left">22</td><td align="left">11</td><td align="left">42</td></tr><tr><td align="left">KRAS</td><td align="left">51</td><td align="left">2538</td><td align="left">95</td><td align="left">1</td><td align="left">4</td><td align="left">93</td><td align="left">1787</td><td align="left">8653</td><td align="left">14</td><td align="left">218</td></tr><tr><td align="left">DNAH8</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">3741</td><td align="left">6</td><td align="left">6012</td><td align="left">NA</td><td align="left">24</td><td align="left">44</td></tr><tr><td align="left">LRRK2</td><td align="left">0</td><td align="left">18</td><td align="left">1</td><td align="left">0</td><td align="left">2433</td><td align="left">13</td><td align="left">NA</td><td align="left">7114</td><td align="left">45</td><td align="left">110</td></tr><tr><td align="left">OBSCN</td><td align="left">0</td><td align="left">4</td><td align="left">0</td><td align="left">0</td><td align="left">1171</td><td align="left">2641</td><td align="left">5199</td><td align="left">2055</td><td align="left">NA</td><td align="left">1184</td></tr><tr><td align="left">PRDM10</td><td align="left">0</td><td align="left">1</td><td align="left">2</td><td align="left">0</td><td align="left">7658</td><td align="left">42</td><td align="left">NA</td><td align="left">992</td><td align="left">479</td><td align="left">36</td></tr><tr><td align="left">RANBP2</td><td align="left">0</td><td align="left">12</td><td align="left">1</td><td align="left">0</td><td align="left">148</td><td align="left">164</td><td align="left">40</td><td align="left">1176</td><td align="left">32</td><td align="left">176</td></tr><tr><td align="left">NOTCH1</td><td align="left">15</td><td align="left">486</td><td align="left">23</td><td align="left">1</td><td align="left">61</td><td align="left">18</td><td align="left">7054</td><td align="left">2680</td><td align="left">94</td><td align="left">45</td></tr><tr><td align="left">TAF1</td><td align="left">0</td><td align="left">9</td><td align="left">1</td><td align="left">0</td><td align="left">45</td><td align="left">7954</td><td align="left">5227</td><td align="left">171</td><td align="left">NA</td><td align="left">8657</td></tr><tr><td align="left">ARID1A</td><td align="left">14</td><td align="left">67</td><td align="left">4</td><td align="left">1</td><td align="left">31</td><td align="left">5994</td><td align="left">4505</td><td align="left">2</td><td align="left">3</td><td align="left">1260</td></tr><tr><td align="left">ANK3</td><td align="left">0</td><td align="left">4</td><td align="left">2</td><td align="left">0</td><td align="left">216</td><td align="left">5214</td><td align="left">5808</td><td align="left">157</td><td align="left">NA</td><td align="left">1914</td></tr><tr><td align="left">ATM</td><td align="left">4</td><td align="left">1222</td><td align="left">5</td><td align="left">1</td><td align="left">241</td><td align="left">54</td><td align="left">1097</td><td align="left">493</td><td align="left">16</td><td align="left">148</td></tr><tr><td align="left">ALB</td><td align="left">0</td><td align="left">32</td><td align="left">1</td><td align="left">0</td><td align="left">7085</td><td align="left">25</td><td align="left">7566</td><td align="left">7390</td><td align="left">397</td><td align="left">37</td></tr><tr><td align="left">EP300</td><td align="left">2</td><td align="left">145</td><td align="left">2</td><td align="left">0</td><td align="left">18</td><td align="left">151</td><td align="left">79</td><td align="left">17</td><td align="left">54</td><td align="left">430</td></tr><tr><td align="left">DMD</td><td align="left">0</td><td align="left">19</td><td align="left">3</td><td align="left">0</td><td align="left">180</td><td align="left">69</td><td align="left">2776</td><td align="left">3448</td><td align="left">NA</td><td align="left">508</td></tr><tr><td align="left">MTOR</td><td align="left">63</td><td align="left">1896</td><td align="left">21</td><td align="left">1</td><td align="left">182</td><td align="left">112</td><td align="left">NA</td><td align="left">1308</td><td align="left">95</td><td align="left">63</td></tr><tr><td align="left">PRKDC</td><td align="left">3</td><td align="left">274</td><td align="left">4</td><td align="left">0</td><td align="left">337</td><td align="left">40</td><td align="left">1217</td><td align="left">41</td><td align="left">28</td><td align="left">130</td></tr><tr><td align="left">CTCF</td><td align="left">2</td><td align="left">50</td><td align="left">3</td><td align="left">1</td><td align="left">1214</td><td align="left">29</td><td align="left">24</td><td align="left">19</td><td align="left">NA</td><td align="left">164</td></tr><tr><td align="left">TTN</td><td align="left">0</td><td align="left">8</td><td align="left">1</td><td align="left">0</td><td align="left">12</td><td align="left">7696</td><td align="left">3</td><td align="left">1195</td><td align="left">NA</td><td align="left">4116</td></tr><tr><td align="left">FGFR2</td><td align="left">23</td><td align="left">294</td><td align="left">5</td><td align="left">1</td><td align="left">177</td><td align="left">55</td><td align="left">4875</td><td align="left">1394</td><td align="left">43</td><td align="left">80</td></tr><tr><td align="left">CAD</td><td align="left">0</td><td align="left">40</td><td align="left">1</td><td align="left">0</td><td align="left">17</td><td align="left">27</td><td align="left">7174</td><td align="left">1091</td><td align="left">122</td><td align="left">51</td></tr><tr><td align="left">NSD1</td><td align="left">0</td><td align="left">16</td><td align="left">2</td><td align="left">1</td><td align="left">1167</td><td align="left">53</td><td align="left">34</td><td align="left">631</td><td align="left">21</td><td align="left">85</td></tr><tr><td align="left">ASH1L</td><td align="left">0</td><td align="left">2</td><td align="left">1</td><td align="left">0</td><td align="left">1279</td><td align="left">4694</td><td align="left">4260</td><td align="left">3296</td><td align="left">49</td><td align="left">2436</td></tr><tr><td align="left">TRRAP</td><td align="left">0</td><td align="left">26</td><td align="left">1</td><td align="left">0</td><td align="left">81</td><td align="left">299</td><td align="left">8</td><td align="left">96</td><td align="left">30</td><td align="left">303</td></tr><tr><td align="left">POTEE</td><td align="left">0</td><td align="left">9</td><td align="left">0</td><td align="left">0</td><td align="left">4902</td><td align="left">155</td><td align="left">NA</td><td align="left">4873</td><td align="left">171</td><td align="left">146</td></tr><tr><td align="left">GLI3</td><td align="left">2</td><td align="left">36</td><td align="left">2</td><td align="left">0</td><td align="left">21</td><td align="left">20</td><td align="left">2263</td><td align="left">3088</td><td align="left">NA</td><td align="left">104</td></tr><tr><td align="left">KMT2D</td><td align="left">0</td><td align="left">18</td><td align="left">1</td><td align="left">1</td><td align="left">23</td><td align="left">NA</td><td align="left">NA</td><td align="left">3113</td><td align="left">NA</td><td align="left">8652</td></tr></tbody></table></table-wrap></p>
        <p id="Par48">We performed GAD and pathway enrichment analysis of these candidate genes (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig S7). In terms of GAD enrichment analysis, these genes are enriched in "endometrial cancer", etc. In pathway enrichment analysis, they significantly enriched in Endometrial cancer. 70% of the top ranked genes have the shortest path to cancer phenotypes in CancerGeneNet database. PRKDC is linked with âAngiogenesisâ, âCell deathâ, âDifferentiationâ, âDNA repairâ, âGlycolysisâ, âImmortalityâ, Metastasisâ and âProliferationâ (Additional file <xref rid="MOESM5" ref-type="media">5</xref>). 83.3% of these candidate genes have related drugs in iGMDR online database (Additional file <xref rid="MOESM6" ref-type="media">6</xref>).</p>
      </sec>
      <sec id="Sec13">
        <title>The stability of the performance across 31 cancer types</title>
        <p id="Par49">Furthermore, we compared the performance of DriverRWH with 24 up-to-date driver gene prediction methods in order to assess the stability of DriverRWH across 31 cancer types. For DriverRWH and six methods mentioned above which provide ranks of the candidate driver gene, top 30 genes were selected as significant drivers [<xref ref-type="bibr" rid="CR59">59</xref>]. For those methods that generate <italic>P</italic>-values, an adjusted <italic>P</italic>-valuesâ&lt;â0.05 was used as the threshold to claim driver genes [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. The details of tools and the criteria for candidate driver genes are provided in the Additional file <xref rid="MOESM7" ref-type="media">7</xref>. FigureÂ <xref rid="Fig6" ref-type="fig">6</xref> displays the proportion of predicted driver genes presented in the reference driver set across 31 cancer types, arranged by the order of the median. DriverRWH recovered approximately 50% (median fraction is 53.3%) of known driver genes in the top 30 ranked candidate genes in more than half of 31 cancer types, which is significantly better than the results of the other methods.<fig id="Fig6"><label>Fig. 6</label><caption><p>The performance of 25 driver gene prediction methods. Distribution of the fraction of predicted candidate driver genes presented in the reference driver set across 31 cancer types</p></caption><graphic xlink:href="12859_2022_4788_Fig6_HTML" id="MO6"/></fig></p>
      </sec>
      <sec id="Sec14">
        <title>Robustness of DriverRWH</title>
        <p id="Par50">To test the robustness of DriverRWH, we applied our method to perturbed data where the mutation data and network data were shuffled randomly (Fig.Â <xref rid="Fig7" ref-type="fig">7</xref>). In detail, for the mutation data, two types of perturbations were taken: (1) randomly selecting 50% and 10% of the samples and (2) randomly selecting 50% and 10% of the original mutation information in the somatic mutation matrix. With 20 repeats, we used only 50% and 10% of samples and 50% of mutation information. There is no significant decrease in terms of the AUC scores and the cumulative number of recovered driver genes. If only 10% of mutation information was retained, there would be a slight decrease. Itâs worth noting that the performance of the top 20 candidates was always at a high level. For the network data, two forms of perturbation were also taken: (1) randomly selecting 50% and 10% of the original network information and (2) using PPI data with 50% and 10% noise added. There was also only a minor decrease in the AUC scores and the cumulative number of recovered cancer genes. A similar conclusion could be obtained when performing robust analysis basing on HumanNet (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig S8). These results suggest that the perturbation of mutation data and the network did not seriously affect the result, indicating that DriverRWH is highly robust to the quality of the input data. <fig id="Fig7"><label>Fig. 7</label><caption><p>Robustness of DriverRWH. <bold>A</bold>, <bold>B</bold> Boxplots of the effects of different data perturbations on the performance of DriverRWH. The vertical lines represent the AUC scores by DriverRWH using all of the data. <bold>C</bold>, <bold>D</bold> Effects of different data perturbations on the performance of DriverRWH measured by the average cumulative number of known cancer genes recovered in the 20, 50, 100, 150, and 200 top-ranked candidate genes</p></caption><graphic xlink:href="12859_2022_4788_Fig7_HTML" id="MO7"/></fig></p>
      </sec>
    </sec>
  </sec>
  <sec id="Sec15">
    <title>Discussion</title>
    <p id="Par51">Recent years, many methods have been developed to distinguish driver genes from passengers. Limited by the design of the simple network model, most of them are incapable of expressing the many-to-many multiple association relationship. The mutation profile was always compressed into the mutation frequency of genes, resulting in the loss of co-mutation information for individual samples. In this study, we propose a network-based method DriverRWH, which has the capability of effectively integrating the mutation and PPI network data to predict cancer driver genes. The novelty of our method lies in the introduction of a weighted hypergraph model, which is constructed to simultaneously capture two class of relation among mutated genes in individual samples: 1) high-order relations were captured by storing hundreds of mutated genes in a hyperedge for each sample. 2) using the same mutated genes as above, an induced subnetwork of PPI network can be generated by preserving mutated genes and their interaction in the background network, which represents the pair-wise relations between mutated genes. Our model retains complete co-mutation relations for the mutated genes in individual tumors and these interactions in PPI network, which can adequately embody the implicit inherent peculiarity of them and avoid the loss of information. Taking advantage of hypergraph structure, we extended the typical random walk process on a simple graph to a probabilistic weighted random walk on hypergraph.</p>
    <p id="Par52">Using a reference driver gene set as a benchmark, DriverRWH consistently outperformed the other six state-of-art prioritization methods in terms of the ROC analysis, rank of driver genes and the cumulative number of known driver genes recovered in the top-ranked candidate genes. Moreover, some new unknown potential driver genes which are co-cited by some cancer associated literatures also can be discovered by DriverRWH, meanwhile the high-ranking genes enrich in some significant cancer pathway. At last, taking top 30 as predicted candidate driver genes, we can compare DriverRWH with other non-ranking methods. The results shows that DriverRWH achieves a higher performance than four prioritization methods and 19 other non-ranking methods across 31 cancer types.</p>
    <p id="Par53">Despite of these encouraging results, there are several limitations in the current model. First, for TCGA data, tumor heterogeneity may increase the data bias, and future work should be done to reduce false-positive discoveries by using single-cell genomics data. Second, DriverRWH relies on a broad context molecular network that is still incomplete at present, so refined gene functional networks in the near future could improve the performance of our method. A cancer-specific network might better represent the natural interactions of genes in cancer and potentially provide a more reliable network. Third, our method focuses on general driver gene detection but does not aim to offer personalized means of diagnosis, which is more useful in real applications. In the future, we plan to extend our method to discover drivers in personalized manner.</p>
  </sec>
  <sec id="Sec16">
    <title>Conclusions</title>
    <p id="Par54">Recently, many computational methods and tools have been proposed to identify driver genes. However, long-tail distribution of the mutation frequency of genes in cancer genomes remains a major concern. There are many widely accepted methods based on mutation frequencies, but they fail to comprehensively consider the co-mutation information in individuals. Considering hypergraph has unique advantages of retaining complete co-occurrence information, we introduced the hypergraph theory in driver gene prediction, thus compensating for the co-mutation information loss issue by existing methods. For each hyperedge, degrees of vertex in the corresponding subnetwork of the PPI network were utilized to design the weighted hypergraph, through which we realized the integration of the mutation data and the PPI data. Subsequently, motivated by PageRank algorithm, we implemented the random walk with restart on the hypergraph, and proposed a novel approach DriverRWH to prioritize mutated genes. As demonstrated in this paper, DriverRWH not only excels existing methods in the identification of known driver genes but also is capable of discovering potential driver genes. Furthermore, the model behaves robustly under the perturbation of mutation data and network data. Our results show that DriverRWH can be a useful tool for prioritization driver genes. The source code of DriverRWH is freely available at <ext-link ext-link-type="uri" xlink:href="https://github.com/ShandongUniversityZhanglab/DriverRWH">https://github.com/ShandongUniversityZhanglab/DriverRWH</ext-link>.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Information</title>
    <sec id="Sec17">
      <p>
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="12859_2022_4788_MOESM1_ESM.docx">
            <caption>
              <p><bold>Additional file1</bold>. <bold> Figure S1</bold>: Boxplot comparing the degrees of known driver and the other genes in induced subnetwork.<bold> Figure S2</bold>: Prediction performance of DriverRWH based on the reference driver set in HumanNet of LUSC.<bold> Figure S3</bold>: The KEGG pathway enrichment analysis for the candidate driver genes of LUSC.<bold> Figure S4</bold>: Prediction performance of DriverRWH based on the reference driver set in HumanNet of BRCA.<bold> Figure S5</bold>: The KEGG pathway enrichment analysis for the candidate driver genes of BRCA.<bold> Figure S6</bold>: Prediction performance of DriverRWH based on the reference driver set in HumanNet of UCEC.<bold> Figure S7</bold>: The KEGG pathway enrichment analysis for the candidate driver genes of UCEC.<bold> Figure S8</bold>: Robustness of DriverRWH in HumanNet.<bold> Table S1</bold>: Cociter mining analysis of top 30 LUSC candidate driver genes identified by DriverRWH (HumanNet).<bold> Table S2</bold>: Cociter mining analysis of top 30 BRCA candidate driver genes identified by DriverRWH (HumanNet).<bold> Table S3</bold>: Cociter mining analysis of top 30 UCEC candidate driver genes identified by DriverRWH (HumanNet).</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM2">
          <media xlink:href="12859_2022_4788_MOESM2_ESM.xls">
            <caption>
              <p><bold>Additional file2</bold>. The details for 31 cancer types used in this work.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM3">
          <media xlink:href="12859_2022_4788_MOESM3_ESM.xls">
            <caption>
              <p><bold>Additional file3</bold>. The known driver gene lists used in this work. </p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM4">
          <media xlink:href="12859_2022_4788_MOESM4_ESM.xls">
            <caption>
              <p><bold>Additional file4</bold>. The top 200 candidate driver genes predicted by DriverRWH, MutsigCV, Gravity, OncodriveFML, Dawnrank, Subdyquency, : and MinNetRank for three cancer types (LUSC, BRCA, UCEC).</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM5">
          <media xlink:href="12859_2022_4788_MOESM5_ESM.xls">
            <caption>
              <p><bold>Additional file5</bold>. The linkages between significant drivers and hallmarks of cancer using CancerGeneNet online database</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM6">
          <media xlink:href="12859_2022_4788_MOESM6_ESM.xls">
            <caption>
              <p><bold>Additional file6</bold>. The gene-drug analysis results of significant drivers using iGMDR online database</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM7">
          <media xlink:href="12859_2022_4788_MOESM7_ESM.xlsx">
            <caption>
              <p><bold>Additional file7</bold>. The details of 24 tools and the criteria for candidate driver genes.</p>
            </caption>
          </media>
        </supplementary-material>
      </p>
    </sec>
  </sec>
</body>
<back>
  <glossary>
    <title>Abbreviations</title>
    <def-list>
      <def-item>
        <term>TCGA</term>
        <def>
          <p id="Par4">The cancer genome atlas</p>
        </def>
      </def-item>
      <def-item>
        <term>NGS</term>
        <def>
          <p id="Par5">Next-generation sequencing</p>
        </def>
      </def-item>
      <def-item>
        <term>SNV</term>
        <def>
          <p id="Par6">Single nucleotide variants</p>
        </def>
      </def-item>
      <def-item>
        <term>BRCA</term>
        <def>
          <p id="Par7">Breast invasive carcinoma</p>
        </def>
      </def-item>
      <def-item>
        <term>LUSC</term>
        <def>
          <p id="Par8">Lung squamous cell carcinoma</p>
        </def>
      </def-item>
      <def-item>
        <term>UCEC</term>
        <def>
          <p id="Par9">Uterine corpus endometrial carcinoma</p>
        </def>
      </def-item>
      <def-item>
        <term>ROC</term>
        <def>
          <p id="Par10">Receiver operating characteristic</p>
        </def>
      </def-item>
      <def-item>
        <term>AUC</term>
        <def>
          <p id="Par11">Area under curve</p>
        </def>
      </def-item>
      <def-item>
        <term>PPI</term>
        <def>
          <p id="Par12">Protein to protein interaction network</p>
        </def>
      </def-item>
      <def-item>
        <term>CGC</term>
        <def>
          <p id="Par13">Cancer gene census</p>
        </def>
      </def-item>
      <def-item>
        <term>HCD</term>
        <def>
          <p id="Par14">High confidence cancer driver genes</p>
        </def>
      </def-item>
      <def-item>
        <term>GAD</term>
        <def>
          <p id="Par15">Genetic association database</p>
        </def>
      </def-item>
    </def-list>
  </glossary>
  <fn-group>
    <fn>
      <p>
        <bold>Publisher's Note</bold>
      </p>
      <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
    <fn>
      <p>Chenye Wang, Junhan Shi and Jiansheng Cai should be regarded as Joint First Authors</p>
    </fn>
  </fn-group>
  <ack>
    <title>Acknowledgements</title>
    <p>The results here are in whole or part based upon data generated by the TCGA Research Network: <ext-link ext-link-type="uri" xlink:href="http://cancergenome.nih.gov/">http://cancergenome.nih.gov/</ext-link>.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Author contributions</title>
    <p>This project was designed and supervised by NZ. NZ, JC, YZ and XZ proposed the hypergraph model. NZ, CW and JS designed and performed the data analyses. JS implemented the software package. The manuscript was written by NZ, CW and JS. All authors read and approved the final manuscript.</p>
  </notes>
  <notes notes-type="funding-information">
    <title>Funding</title>
    <p>This work has been supported by the National Natural Science Foundation of China [62072277 to NZ, 61972257 to XZ, 61877064 to YZ, 12071351 to JC].</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Availability of data and materials</title>
    <p>The source code and example datasets used in this research can be download form <ext-link ext-link-type="uri" xlink:href="https://github.com/ShandongUniversityZhanglab/DriverRWH">https://github.com/ShandongUniversityZhanglab/DriverRWH</ext-link></p>
  </notes>
  <notes>
    <title>Declarations</title>
    <notes id="FPar1">
      <title>Ethics approval and consent to participate</title>
      <p id="Par55">The data analyzed in this study were from public databases, so ethical approval and consent participation were not required. All methods in this study were performed in accordance with the relevant guidelines and regulations.</p>
    </notes>
    <notes id="FPar2">
      <title>Consent for publication</title>
      <p id="Par56">Not applicable.</p>
    </notes>
    <notes id="FPar3" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par57">The authors declare that they have no competing interests.</p>
    </notes>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Stratton</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Campbell</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>Futreal</surname>
            <given-names>PA</given-names>
          </name>
        </person-group>
        <article-title>The cancer genome</article-title>
        <source>Nature</source>
        <year>2009</year>
        <volume>458</volume>
        <issue>7239</issue>
        <fpage>719</fpage>
        <lpage>724</lpage>
        <pub-id pub-id-type="doi">10.1038/nature07943</pub-id>
        <?supplied-pmid 19360079?>
        <pub-id pub-id-type="pmid">19360079</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Stratton</surname>
            <given-names>MR</given-names>
          </name>
        </person-group>
        <article-title>Exploring the genomes of cancer cells: progress and promise</article-title>
        <source>Science</source>
        <year>2011</year>
        <volume>331</volume>
        <issue>6024</issue>
        <fpage>1553</fpage>
        <lpage>1558</lpage>
        <pub-id pub-id-type="doi">10.1126/science.1204040</pub-id>
        <?supplied-pmid 21436442?>
        <pub-id pub-id-type="pmid">21436442</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chin</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Meyerson</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Aldape</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Bigner</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Mikkelsen</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>VandenBerg</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kahn</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Penny</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Ferguson</surname>
            <given-names>ML</given-names>
          </name>
          <name>
            <surname>Gerhard</surname>
            <given-names>DS</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Comprehensive genomic characterization defines human glioblastoma genes and core pathways</article-title>
        <source>Nature</source>
        <year>2008</year>
        <volume>455</volume>
        <issue>7216</issue>
        <fpage>1061</fpage>
        <lpage>1068</lpage>
        <pub-id pub-id-type="doi">10.1038/nature07385</pub-id>
        <pub-id pub-id-type="pmid">18772890</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Martinez-Jimenez</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Muinos</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Sentis</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Deu-Pons</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Reyes-Salazar</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Arnedo-Pac</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Mularoni</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Pich</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Bonet</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Kranas</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A compendium of mutational cancer driver genes</article-title>
        <source>Nat Rev Cancer</source>
        <year>2020</year>
        <volume>20</volume>
        <issue>10</issue>
        <fpage>555</fpage>
        <lpage>572</lpage>
        <pub-id pub-id-type="doi">10.1038/s41568-020-0290-x</pub-id>
        <?supplied-pmid 32778778?>
        <pub-id pub-id-type="pmid">32778778</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Brin</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Page</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>The anatomy of a large-scale hypertextual Web search engine</article-title>
        <source>Comput Netw ISDN Syst</source>
        <year>1998</year>
        <volume>30</volume>
        <issue>1â7</issue>
        <fpage>107</fpage>
        <lpage>117</lpage>
        <pub-id pub-id-type="doi">10.1016/S0169-7552(98)00110-X</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bert Vogelstein</surname>
            <given-names>NP</given-names>
          </name>
          <name>
            <surname>Velculescu</surname>
            <given-names>VE</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Diaz Jr</surname>
            <given-names>LA</given-names>
          </name>
          <name>
            <surname>Kinzler</surname>
            <given-names>KW</given-names>
          </name>
        </person-group>
        <article-title>Cancer genome landscapes</article-title>
        <source>Science</source>
        <year>2013</year>
        <volume>339</volume>
        <issue>6127</issue>
        <fpage>1546</fpage>
        <lpage>1558</lpage>
        <pub-id pub-id-type="doi">10.1126/science.1235122</pub-id>
        <?supplied-pmid 23539594?>
        <pub-id pub-id-type="pmid">23539594</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Han</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Qian</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>WC</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>SH</given-names>
          </name>
          <name>
            <surname>Hua</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>P</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>DriverML: a machine learning algorithm for identifying driver genes in cancer sequencing studies</article-title>
        <source>Nucleic Acids Res</source>
        <year>2019</year>
        <volume>47</volume>
        <issue>8</issue>
        <fpage>e45</fpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkz096</pub-id>
        <?supplied-pmid 30773592?>
        <pub-id pub-id-type="pmid">30773592</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lawrence</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Stojanov</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Polak</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Kryukov</surname>
            <given-names>GV</given-names>
          </name>
          <name>
            <surname>Cibulskis</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Sivachenko</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Carter</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Stewart</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Mermel</surname>
            <given-names>CH</given-names>
          </name>
          <name>
            <surname>Roberts</surname>
            <given-names>SA</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mutational heterogeneity in cancer and the search for new cancer-associated genes</article-title>
        <source>Nature</source>
        <year>2013</year>
        <volume>499</volume>
        <issue>7457</issue>
        <fpage>214</fpage>
        <lpage>218</lpage>
        <pub-id pub-id-type="doi">10.1038/nature12213</pub-id>
        <?supplied-pmid 23770567?>
        <pub-id pub-id-type="pmid">23770567</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Reimand</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wagih</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Bader</surname>
            <given-names>GD</given-names>
          </name>
        </person-group>
        <article-title>The mutational landscape of phosphorylation signaling in cancer</article-title>
        <source>Sci Rep</source>
        <year>2013</year>
        <volume>3</volume>
        <fpage>1</fpage>
        <lpage>9</lpage>
        <pub-id pub-id-type="doi">10.1038/srep02651</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cheng</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>Z</given-names>
          </name>
        </person-group>
        <article-title>Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes</article-title>
        <source>Brief Bioinform</source>
        <year>2016</year>
        <volume>17</volume>
        <issue>4</issue>
        <fpage>642</fpage>
        <lpage>656</lpage>
        <pub-id pub-id-type="doi">10.1093/bib/bbv068</pub-id>
        <?supplied-pmid 26307061?>
        <pub-id pub-id-type="pmid">26307061</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gonzalez-Perez</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Lopez-Bigas</surname>
            <given-names>N</given-names>
          </name>
        </person-group>
        <article-title>Functional impact bias reveals cancer drivers</article-title>
        <source>Nucleic Acids Res</source>
        <year>2012</year>
        <volume>40</volume>
        <issue>21</issue>
        <fpage>e169</fpage>
        <pub-id pub-id-type="doi">10.1093/nar/gks743</pub-id>
        <?supplied-pmid 22904074?>
        <pub-id pub-id-type="pmid">22904074</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>S-W</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>YJB</given-names>
          </name>
        </person-group>
        <article-title>Identifying driver genes for individual patients through inductive matrix completion</article-title>
        <source>Bioinformatics</source>
        <year>2021</year>
        <volume>37</volume>
        <issue>23</issue>
        <fpage>4477</fpage>
        <lpage>4484</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btab477</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gao</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>GJ</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>JT</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>XZ</given-names>
          </name>
        </person-group>
        <article-title>Identification of driver modules in pan-cancer via coordinating coverage and exclusivity</article-title>
        <source>Oncotarget</source>
        <year>2017</year>
        <volume>8</volume>
        <issue>22</issue>
        <fpage>36115</fpage>
        <lpage>36126</lpage>
        <pub-id pub-id-type="doi">10.18632/oncotarget.16433</pub-id>
        <?supplied-pmid 28415609?>
        <pub-id pub-id-type="pmid">28415609</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hou</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>DawnRank: discovering personalized driver genes in cancer</article-title>
        <source>Genome Med</source>
        <year>2014</year>
        <volume>6</volume>
        <fpage>1</fpage>
        <lpage>16</lpage>
        <pub-id pub-id-type="doi">10.1186/s13073-014-0056-8</pub-id>
        <pub-id pub-id-type="pmid">24433494</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Leiserson</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Vandin</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>HT</given-names>
          </name>
          <name>
            <surname>Dobson</surname>
            <given-names>JR</given-names>
          </name>
          <name>
            <surname>Eldridge</surname>
            <given-names>JV</given-names>
          </name>
          <name>
            <surname>Thomas</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Papoutsaki</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Niu</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>McLellan</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes</article-title>
        <source>Nat Genet</source>
        <year>2015</year>
        <volume>47</volume>
        <issue>2</issue>
        <fpage>106</fpage>
        <lpage>114</lpage>
        <pub-id pub-id-type="doi">10.1038/ng.3168</pub-id>
        <?supplied-pmid 25501392?>
        <pub-id pub-id-type="pmid">25501392</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wei</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Fa</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Luo</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Johnston</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>Z</given-names>
          </name>
        </person-group>
        <article-title>An efficient and easy-to-use network-based integrative method of multi-omics data for cancer genes discovery</article-title>
        <source>Front Genet</source>
        <year>2021</year>
        <volume>11</volume>
        <fpage>1631</fpage>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Song</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Peng</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>FJ</given-names>
          </name>
        </person-group>
        <article-title>A random walk-based method to identify driver genes by integrating the subcellular localization and variation frequency into bipartite graph</article-title>
        <source>BMC Bioinformatics</source>
        <year>2019</year>
        <volume>20</volume>
        <issue>1</issue>
        <fpage>1</fpage>
        <lpage>17</lpage>
        <pub-id pub-id-type="doi">10.1186/s12859-018-2565-8</pub-id>
        <pub-id pub-id-type="pmid">30606105</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cheng</surname>
            <given-names>W-C</given-names>
          </name>
          <name>
            <surname>Chung</surname>
            <given-names>IF</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>C-Y</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>H-J</given-names>
          </name>
          <name>
            <surname>Fen</surname>
            <given-names>J-J</given-names>
          </name>
          <name>
            <surname>Tang</surname>
            <given-names>W-C</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>T-Y</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>T-T</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>H-W</given-names>
          </name>
        </person-group>
        <article-title>DriverDB: an exome sequencing database for cancer driver gene identification</article-title>
        <source>Nucleic Acids Res</source>
        <year>2014</year>
        <volume>42</volume>
        <issue>D1</issue>
        <fpage>D1048</fpage>
        <lpage>D1054</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkt1025</pub-id>
        <?supplied-pmid 24214964?>
        <pub-id pub-id-type="pmid">24214964</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Skoulidis</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Heymach</surname>
            <given-names>JV</given-names>
          </name>
        </person-group>
        <article-title>Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy</article-title>
        <source>Nat Rev Cancer</source>
        <year>2019</year>
        <volume>19</volume>
        <issue>9</issue>
        <fpage>495</fpage>
        <lpage>509</lpage>
        <pub-id pub-id-type="doi">10.1038/s41568-019-0179-8</pub-id>
        <?supplied-pmid 31406302?>
        <pub-id pub-id-type="pmid">31406302</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Uren</surname>
            <given-names>AG</given-names>
          </name>
          <name>
            <surname>Kool</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Matentzoglu</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>de Ridder</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Mattison</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>van Uitert</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lagcher</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Sie</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Tanger</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Cox</surname>
            <given-names>T</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Large-scale mutagenesis in p19(ARF)- and p53- deficient mice identifies cancer genes and their collaborative networks</article-title>
        <source>Cell</source>
        <year>2008</year>
        <volume>133</volume>
        <issue>4</issue>
        <fpage>727</fpage>
        <lpage>741</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2008.03.021</pub-id>
        <?supplied-pmid 18485879?>
        <pub-id pub-id-type="pmid">18485879</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ding</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Getz</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Wheeler</surname>
            <given-names>DA</given-names>
          </name>
          <name>
            <surname>Mardis</surname>
            <given-names>ER</given-names>
          </name>
          <name>
            <surname>McLellan</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Cibulskis</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Sougnez</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Greulich</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Muzny</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Morgan</surname>
            <given-names>MB</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Somatic mutations affect key pathways in lung adenocarcinoma</article-title>
        <source>Nature</source>
        <year>2008</year>
        <volume>455</volume>
        <issue>7216</issue>
        <fpage>1069</fpage>
        <lpage>1075</lpage>
        <pub-id pub-id-type="doi">10.1038/nature07423</pub-id>
        <?supplied-pmid 18948947?>
        <pub-id pub-id-type="pmid">18948947</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Martincorena</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Raine</surname>
            <given-names>KM</given-names>
          </name>
          <name>
            <surname>Gerstung</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Dawson</surname>
            <given-names>KJ</given-names>
          </name>
          <name>
            <surname>Haase</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Van Loo</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Davies</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Stratton</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Campbell</surname>
            <given-names>PJ</given-names>
          </name>
        </person-group>
        <article-title>Universal patterns of selection in cancer and somatic tissues</article-title>
        <source>Cell</source>
        <year>2017</year>
        <volume>171</volume>
        <issue>5</issue>
        <fpage>1029</fpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2017.09.042</pub-id>
        <?supplied-pmid 29056346?>
        <pub-id pub-id-type="pmid">29056346</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Torti</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Trusolino</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils</article-title>
        <source>EMBO Mol Med</source>
        <year>2011</year>
        <volume>3</volume>
        <issue>11</issue>
        <fpage>623</fpage>
        <lpage>636</lpage>
        <pub-id pub-id-type="doi">10.1002/emmm.201100176</pub-id>
        <?supplied-pmid 21953712?>
        <pub-id pub-id-type="pmid">21953712</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hahn</surname>
            <given-names>WC</given-names>
          </name>
          <name>
            <surname>Weinberg</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>Modelling the molecular circuitry of cancer</article-title>
        <source>Nat Rev Cancer</source>
        <year>2002</year>
        <volume>2</volume>
        <issue>5</issue>
        <fpage>331</fpage>
        <lpage>341</lpage>
        <pub-id pub-id-type="doi">10.1038/nrc795</pub-id>
        <?supplied-pmid 12044009?>
        <pub-id pub-id-type="pmid">12044009</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hahn</surname>
            <given-names>WC</given-names>
          </name>
          <name>
            <surname>Counter</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Lundberg</surname>
            <given-names>AS</given-names>
          </name>
          <name>
            <surname>Beijersbergen</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Brooks</surname>
            <given-names>MW</given-names>
          </name>
          <name>
            <surname>Weinberg</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>Creation of human tumour cells with defined genetic elements</article-title>
        <source>Nature</source>
        <year>1999</year>
        <volume>400</volume>
        <issue>6743</issue>
        <fpage>464</fpage>
        <lpage>468</lpage>
        <pub-id pub-id-type="doi">10.1038/22780</pub-id>
        <?supplied-pmid 10440377?>
        <pub-id pub-id-type="pmid">10440377</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>Bretto</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <source>Hypergraph theory-an introduction</source>
        <year>2013</year>
        <publisher-loc>Switzerland</publisher-loc>
        <publisher-name>Springer</publisher-name>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>SY</given-names>
          </name>
          <name>
            <surname>Ding</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Cui</surname>
            <given-names>SG</given-names>
          </name>
        </person-group>
        <article-title>Introducing Hypergraph Signal Processing: Theoretical Foundation and Practical Applications</article-title>
        <source>IEEE Internet Things J</source>
        <year>2020</year>
        <volume>7</volume>
        <issue>1</issue>
        <fpage>639</fpage>
        <lpage>660</lpage>
        <pub-id pub-id-type="doi">10.1109/JIOT.2019.2950213</pub-id>
      </element-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <mixed-citation publication-type="other">Barbarossa S, Tsitsvero M. Ieee: an introduction to hypergraph signal processing. In: 41st IEEE International Conference on Acoustics, Speech and Signal Processing (ICASSP): Mar 20â25 2016; Shanghai, Peoples R China. 2016: 6425â6429.</mixed-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tomczak</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Czerwinska</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Wiznerowicz</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>The cancer genome atlas (TCGA): an immeasurable source of knowledge</article-title>
        <source>Contempor Oncol (Poznan, Poland)</source>
        <year>2015</year>
        <volume>19</volume>
        <issue>1A</issue>
        <fpage>A68</fpage>
        <lpage>77</lpage>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Szklarczyk</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Franceschini</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Wyder</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Forslund</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Heller</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Huerta-Cepas</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Simonovic</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Roth</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Santos</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Tsafou</surname>
            <given-names>KP</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>STRING v10: protein-protein interaction networks, integrated over the tree of life</article-title>
        <source>Nucleic Acids Res</source>
        <year>2015</year>
        <volume>43</volume>
        <issue>Database issue</issue>
        <fpage>D447</fpage>
        <lpage>452</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gku1003</pub-id>
        <?supplied-pmid 25352553?>
        <pub-id pub-id-type="pmid">25352553</pub-id>
      </element-citation>
    </ref>
    <ref id="CR31">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Blom</surname>
            <given-names>UM</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>PI</given-names>
          </name>
          <name>
            <surname>Shim</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Marcotte</surname>
            <given-names>EM</given-names>
          </name>
        </person-group>
        <article-title>Prioritizing candidate disease genes by network-based boosting of genome-wide association data</article-title>
        <source>Genome Res</source>
        <year>2011</year>
        <volume>21</volume>
        <issue>7</issue>
        <fpage>1109</fpage>
        <lpage>1121</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.118992.110</pub-id>
        <?supplied-pmid 21536720?>
        <pub-id pub-id-type="pmid">21536720</pub-id>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Forbes</surname>
            <given-names>SA</given-names>
          </name>
          <name>
            <surname>Beare</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Boutselakis</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Bamford</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bindal</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Tate</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Cole</surname>
            <given-names>CG</given-names>
          </name>
          <name>
            <surname>Ward</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Dawson</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Ponting</surname>
            <given-names>L</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>COSMIC: somatic cancer genetics at high-resolution</article-title>
        <source>Nucleic Acids Res</source>
        <year>2017</year>
        <volume>45</volume>
        <issue>D1</issue>
        <fpage>D777</fpage>
        <lpage>D783</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkw1121</pub-id>
        <?supplied-pmid 27899578?>
        <pub-id pub-id-type="pmid">27899578</pub-id>
      </element-citation>
    </ref>
    <ref id="CR33">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kumar</surname>
            <given-names>RD</given-names>
          </name>
          <name>
            <surname>Searleman</surname>
            <given-names>AC</given-names>
          </name>
          <name>
            <surname>Swamidass</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Griffith</surname>
            <given-names>OL</given-names>
          </name>
          <name>
            <surname>Bose</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing data</article-title>
        <source>Bioinformatics</source>
        <year>2015</year>
        <volume>31</volume>
        <issue>22</issue>
        <fpage>3561</fpage>
        <lpage>3568</lpage>
        <?supplied-pmid 26209800?>
        <pub-id pub-id-type="pmid">26209800</pub-id>
      </element-citation>
    </ref>
    <ref id="CR34">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Reimand</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wagih</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Bader</surname>
            <given-names>GD</given-names>
          </name>
        </person-group>
        <article-title>The mutational landscape of phosphorylation signaling in cancer</article-title>
        <source>Sci Rep</source>
        <year>2013</year>
        <volume>3</volume>
        <fpage>2651</fpage>
        <pub-id pub-id-type="doi">10.1038/srep02651</pub-id>
        <?supplied-pmid 24089029?>
        <pub-id pub-id-type="pmid">24089029</pub-id>
      </element-citation>
    </ref>
    <ref id="CR35">
      <label>35.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gonzalez-Perez</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Perez-Llamas</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Deu-Pons</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Tamborero</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Schroeder</surname>
            <given-names>MP</given-names>
          </name>
          <name>
            <surname>Jene-Sanz</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Santos</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Lopez-Bigas</surname>
            <given-names>N</given-names>
          </name>
        </person-group>
        <article-title>IntOGen-mutations identifies cancer drivers across tumor types</article-title>
        <source>Nat Methods</source>
        <year>2013</year>
        <volume>10</volume>
        <issue>11</issue>
        <fpage>1081</fpage>
        <lpage>1082</lpage>
        <pub-id pub-id-type="doi">10.1038/nmeth.2642</pub-id>
        <?supplied-pmid 24037244?>
        <pub-id pub-id-type="pmid">24037244</pub-id>
      </element-citation>
    </ref>
    <ref id="CR36">
      <label>36.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Sherman</surname>
            <given-names>BT</given-names>
          </name>
          <name>
            <surname>Lempicki</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists</article-title>
        <source>Nucleic Acids Res</source>
        <year>2009</year>
        <volume>37</volume>
        <issue>1</issue>
        <fpage>1</fpage>
        <lpage>13</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkn923</pub-id>
        <pub-id pub-id-type="pmid">19033363</pub-id>
      </element-citation>
    </ref>
    <ref id="CR37">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Sherman</surname>
            <given-names>BT</given-names>
          </name>
          <name>
            <surname>Lempicki</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title>
        <source>Nat Protoc</source>
        <year>2009</year>
        <volume>4</volume>
        <issue>1</issue>
        <fpage>44</fpage>
        <lpage>57</lpage>
        <pub-id pub-id-type="doi">10.1038/nprot.2008.211</pub-id>
        <pub-id pub-id-type="pmid">19131956</pub-id>
      </element-citation>
    </ref>
    <ref id="CR38">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Iannuccelli</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Micarelli</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Surdo</surname>
            <given-names>PL</given-names>
          </name>
          <name>
            <surname>Palma</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Perfetto</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Rozzo</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Castagnoli</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Licata</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Cesareni</surname>
            <given-names>GJ</given-names>
          </name>
        </person-group>
        <article-title>CancerGeneNet: linking driver genes to cancer hallmarks</article-title>
        <source>Nucleic Acids Research</source>
        <year>2020</year>
        <volume>48</volume>
        <issue>D1</issue>
        <fpage>D416</fpage>
        <lpage>D421</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkz871</pub-id>
        <?supplied-pmid 31598703?>
        <pub-id pub-id-type="pmid">31598703</pub-id>
      </element-citation>
    </ref>
    <ref id="CR39">
      <label>39.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>X</given-names>
          </name>
        </person-group>
        <article-title>iGMDR: integrated pharmacogenetic resource guide to cancer therapy and research</article-title>
        <source>Genomics Proteomics Bioinformatics</source>
        <year>2020</year>
        <volume>18</volume>
        <issue>2</issue>
        <fpage>150</fpage>
        <lpage>160</lpage>
        <pub-id pub-id-type="doi">10.1016/j.gpb.2019.11.011</pub-id>
        <?supplied-pmid 32916316?>
        <pub-id pub-id-type="pmid">32916316</pub-id>
      </element-citation>
    </ref>
    <ref id="CR40">
      <label>40.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Qiao</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Naveed</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Green</surname>
            <given-names>CD</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>JDJ</given-names>
          </name>
        </person-group>
        <article-title>CoCiter: an efficient tool to infer gene function by assessing the significance of literature co-citation</article-title>
        <source>Plos One</source>
        <year>2013</year>
        <volume>8</volume>
        <issue>9</issue>
        <fpage>e74074</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0074074</pub-id>
        <?supplied-pmid 24086311?>
        <pub-id pub-id-type="pmid">24086311</pub-id>
      </element-citation>
    </ref>
    <ref id="CR41">
      <label>41.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cheng</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>CC</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Jia</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>WH</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>Z</given-names>
          </name>
        </person-group>
        <article-title>A gene gravity model for the evolution of cancer genomes: a study of 3,000 cancer genomes across 9 cancer types</article-title>
        <source>PLoS Comput Biol</source>
        <year>2015</year>
        <volume>11</volume>
        <issue>9</issue>
        <fpage>e1004497</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pcbi.1004497</pub-id>
        <?supplied-pmid 26352260?>
        <pub-id pub-id-type="pmid">26352260</pub-id>
      </element-citation>
    </ref>
    <ref id="CR42">
      <label>42.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mularoni</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Sabarinathan</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Deu-Pons</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Gonzalez-Perez</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Lopez-Bigas</surname>
            <given-names>N</given-names>
          </name>
        </person-group>
        <article-title>OncodriveFML: a general framework to identify coding and non-coding regions with cancer driver mutations</article-title>
        <source>Genome Biol</source>
        <year>2016</year>
        <volume>17</volume>
        <issue>1</issue>
        <fpage>128</fpage>
        <pub-id pub-id-type="doi">10.1186/s13059-016-0994-0</pub-id>
        <?supplied-pmid 27311963?>
        <pub-id pub-id-type="pmid">27311963</pub-id>
      </element-citation>
    </ref>
    <ref id="CR43">
      <label>43.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sung</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Ferlay</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Siegel</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Laversanne</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Soerjomataram</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Jemal</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Bray</surname>
            <given-names>F</given-names>
          </name>
        </person-group>
        <article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries</article-title>
        <source>CA Cancer J Clin</source>
        <year>2021</year>
        <volume>71</volume>
        <issue>3</issue>
        <fpage>209</fpage>
        <lpage>249</lpage>
        <pub-id pub-id-type="doi">10.3322/caac.21660</pub-id>
        <?supplied-pmid 33538338?>
        <pub-id pub-id-type="pmid">33538338</pub-id>
      </element-citation>
    </ref>
    <ref id="CR44">
      <label>44.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Becker</surname>
            <given-names>KG</given-names>
          </name>
          <name>
            <surname>Barnes</surname>
            <given-names>KC</given-names>
          </name>
          <name>
            <surname>Bright</surname>
            <given-names>TJ</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>SA</given-names>
          </name>
        </person-group>
        <article-title>The genetic association database</article-title>
        <source>Nat Genet</source>
        <year>2004</year>
        <volume>36</volume>
        <issue>5</issue>
        <fpage>431</fpage>
        <lpage>432</lpage>
        <pub-id pub-id-type="doi">10.1038/ng0504-431</pub-id>
        <?supplied-pmid 15118671?>
        <pub-id pub-id-type="pmid">15118671</pub-id>
      </element-citation>
    </ref>
    <ref id="CR45">
      <label>45.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>L-G</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>QY</given-names>
          </name>
        </person-group>
        <article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title>
        <source>Omics J Integr Biol</source>
        <year>2012</year>
        <volume>16</volume>
        <issue>5</issue>
        <fpage>284</fpage>
        <lpage>287</lpage>
        <pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id>
      </element-citation>
    </ref>
    <ref id="CR46">
      <label>46.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kanehisa</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Furumichi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sato</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Ishiguro-Watanabe</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tanabe</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>KEGG: integrating viruses and cellular organisms</article-title>
        <source>Nucleic Acids Res</source>
        <year>2021</year>
        <volume>49</volume>
        <issue>D1</issue>
        <fpage>D545</fpage>
        <lpage>D551</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkaa970</pub-id>
        <?supplied-pmid 33125081?>
        <pub-id pub-id-type="pmid">33125081</pub-id>
      </element-citation>
    </ref>
    <ref id="CR47">
      <label>47.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kanehisa</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Goto</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>KEGG: kyoto encyclopedia of genes and genomes</article-title>
        <source>Nucleic Acids Res</source>
        <year>2000</year>
        <volume>28</volume>
        <issue>1</issue>
        <fpage>27</fpage>
        <lpage>30</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/28.1.27</pub-id>
        <?supplied-pmid 10592173?>
        <pub-id pub-id-type="pmid">10592173</pub-id>
      </element-citation>
    </ref>
    <ref id="CR48">
      <label>48.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kanehisa</surname>
            <given-names>MJ</given-names>
          </name>
        </person-group>
        <article-title>Toward understanding the origin and evolution of cellular organisms</article-title>
        <source>Protein Sci</source>
        <year>2019</year>
        <volume>28</volume>
        <issue>11</issue>
        <fpage>1947</fpage>
        <lpage>1951</lpage>
        <pub-id pub-id-type="doi">10.1002/pro.3715</pub-id>
        <?supplied-pmid 31441146?>
        <pub-id pub-id-type="pmid">31441146</pub-id>
      </element-citation>
    </ref>
    <ref id="CR49">
      <label>49.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tan</surname>
            <given-names>AC</given-names>
          </name>
        </person-group>
        <article-title>Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC)</article-title>
        <source>Thorac Cancer</source>
        <year>2020</year>
        <volume>11</volume>
        <issue>3</issue>
        <fpage>511</fpage>
        <lpage>518</lpage>
        <pub-id pub-id-type="doi">10.1111/1759-7714.13328</pub-id>
        <?supplied-pmid 31989769?>
        <pub-id pub-id-type="pmid">31989769</pub-id>
      </element-citation>
    </ref>
    <ref id="CR50">
      <label>50.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>An</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>ZH</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>QX</given-names>
          </name>
          <name>
            <surname>Su</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>HJ</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>JY</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>YL</given-names>
          </name>
        </person-group>
        <article-title>The-271 G &gt; A polymorphism of kinase insert domain-containing receptor gene regulates its transcription level in patients with non-small cell lung cancer</article-title>
        <source>Bmc Cancer</source>
        <year>2009</year>
        <volume>9</volume>
        <fpage>1</fpage>
        <lpage>6</lpage>
        <pub-id pub-id-type="doi">10.1186/1471-2407-9-144</pub-id>
        <pub-id pub-id-type="pmid">19118499</pub-id>
      </element-citation>
    </ref>
    <ref id="CR51">
      <label>51.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hanahan</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Weinberg</surname>
            <given-names>RAJ</given-names>
          </name>
        </person-group>
        <article-title>Hallmarks of cancer: the next generation</article-title>
        <source>Cell</source>
        <year>2011</year>
        <volume>144</volume>
        <issue>5</issue>
        <fpage>646</fpage>
        <lpage>674</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id>
        <?supplied-pmid 21376230?>
        <pub-id pub-id-type="pmid">21376230</pub-id>
      </element-citation>
    </ref>
    <ref id="CR52">
      <label>52.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Waks</surname>
            <given-names>AG</given-names>
          </name>
          <name>
            <surname>Winer</surname>
            <given-names>EP</given-names>
          </name>
        </person-group>
        <article-title>Breast cancer treatment a review</article-title>
        <source>Jama-J Am Med Assoc</source>
        <year>2019</year>
        <volume>321</volume>
        <issue>3</issue>
        <fpage>288</fpage>
        <lpage>300</lpage>
        <pub-id pub-id-type="doi">10.1001/jama.2018.19323</pub-id>
      </element-citation>
    </ref>
    <ref id="CR53">
      <label>53.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Masuda</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Bartholomeusz</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Doihara</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Hortobagyi</surname>
            <given-names>GN</given-names>
          </name>
          <name>
            <surname>Ueno</surname>
            <given-names>NT</given-names>
          </name>
        </person-group>
        <article-title>Role of epidermal growth factor receptor in breast cancer</article-title>
        <source>Breast Cancer Res Treat</source>
        <year>2012</year>
        <volume>136</volume>
        <issue>2</issue>
        <fpage>331</fpage>
        <lpage>345</lpage>
        <pub-id pub-id-type="doi">10.1007/s10549-012-2289-9</pub-id>
        <?supplied-pmid 23073759?>
        <pub-id pub-id-type="pmid">23073759</pub-id>
      </element-citation>
    </ref>
    <ref id="CR54">
      <label>54.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bray</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Ferlay</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Soerjomataram</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Siegel</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Torre</surname>
            <given-names>LA</given-names>
          </name>
          <name>
            <surname>Jemal</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>
        <source>Ca-a Cancer J Clin</source>
        <year>2018</year>
        <volume>68</volume>
        <issue>6</issue>
        <fpage>394</fpage>
        <lpage>424</lpage>
        <pub-id pub-id-type="doi">10.3322/caac.21492</pub-id>
      </element-citation>
    </ref>
    <ref id="CR55">
      <label>55.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Slomovitz</surname>
            <given-names>BM</given-names>
          </name>
          <name>
            <surname>Coleman</surname>
            <given-names>RL</given-names>
          </name>
        </person-group>
        <article-title>The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer</article-title>
        <source>Clin Cancer Res</source>
        <year>2012</year>
        <volume>18</volume>
        <issue>21</issue>
        <fpage>5856</fpage>
        <lpage>5864</lpage>
        <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-0662</pub-id>
        <?supplied-pmid 23082003?>
        <pub-id pub-id-type="pmid">23082003</pub-id>
      </element-citation>
    </ref>
    <ref id="CR56">
      <label>56.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sasnauskiene</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Jonusiene</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Krikstaponiene</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Butkyte</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Dabkeviciene</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Kanopiene</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Kazbariene</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Didziapetriene</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>NOTCH1, NOTCH3, NOTCH4, and JAG2 protein levels in human endometrial cancer</article-title>
        <source>Medicina-Lithuania</source>
        <year>2014</year>
        <volume>50</volume>
        <issue>1</issue>
        <fpage>14</fpage>
        <lpage>18</lpage>
      </element-citation>
    </ref>
    <ref id="CR57">
      <label>57.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tan</surname>
            <given-names>KT</given-names>
          </name>
          <name>
            <surname>Yeh</surname>
            <given-names>C-N</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>Y-C</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>J-H</given-names>
          </name>
          <name>
            <surname>Fang</surname>
            <given-names>W-L</given-names>
          </name>
          <name>
            <surname>Yeh</surname>
            <given-names>Y-C</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y-C</given-names>
          </name>
          <name>
            <surname>Hsu</surname>
            <given-names>DS-S</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>C-E</given-names>
          </name>
          <name>
            <surname>Lai</surname>
            <given-names>J-I</given-names>
          </name>
        </person-group>
        <article-title>PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy</article-title>
        <source>J Immunother Cancer.</source>
        <year>2020</year>
        <volume>8</volume>
        <issue>1</issue>
        <fpage>1</fpage>
        <lpage>12</lpage>
        <pub-id pub-id-type="doi">10.1136/jitc-2019-000485</pub-id>
      </element-citation>
    </ref>
    <ref id="CR58">
      <label>58.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rizvi</surname>
            <given-names>NA</given-names>
          </name>
          <name>
            <surname>Hellmann</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Snyder</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kvistborg</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Makarov</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Havel</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Yuan</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Ho</surname>
            <given-names>TS</given-names>
          </name>
        </person-group>
        <article-title>Mutational landscape determines sensitivity to PD-1 blockade in nonâsmall cell lung cancer</article-title>
        <source>Science</source>
        <year>2015</year>
        <volume>348</volume>
        <issue>6230</issue>
        <fpage>124</fpage>
        <lpage>128</lpage>
        <pub-id pub-id-type="doi">10.1126/science.aaa1348</pub-id>
        <?supplied-pmid 25765070?>
        <pub-id pub-id-type="pmid">25765070</pub-id>
      </element-citation>
    </ref>
    <ref id="CR59">
      <label>59.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Guo</surname>
            <given-names>W-F</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>S-W</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>L-L</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>Q-Q</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Tang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Zeng</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>Discovering personalized driver mutation profiles of single samples in cancer by network control strategy</article-title>
        <source>Bioinformatics</source>
        <year>2018</year>
        <volume>34</volume>
        <issue>11</issue>
        <fpage>1893</fpage>
        <lpage>1903</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/bty006</pub-id>
        <?supplied-pmid 29329368?>
        <pub-id pub-id-type="pmid">29329368</pub-id>
      </element-citation>
    </ref>
    <ref id="CR60">
      <label>60.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Porta-Pardo</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Godzik</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>e-Driver: a novel method to identify protein regions driving cancer</article-title>
        <source>Bioinformatics</source>
        <year>2014</year>
        <volume>30</volume>
        <issue>21</issue>
        <fpage>3109</fpage>
        <lpage>3114</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btu499</pub-id>
        <?supplied-pmid 25064568?>
        <pub-id pub-id-type="pmid">25064568</pub-id>
      </element-citation>
    </ref>
    <ref id="CR61">
      <label>61.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jia</surname>
            <given-names>PL</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>QX</given-names>
          </name>
          <name>
            <surname>Hutchinson</surname>
            <given-names>KE</given-names>
          </name>
          <name>
            <surname>Pao</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>ZM</given-names>
          </name>
        </person-group>
        <article-title>MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis</article-title>
        <source>Genome Biol</source>
        <year>2014</year>
        <volume>15</volume>
        <issue>10</issue>
        <fpage>1</fpage>
        <lpage>16</lpage>
        <pub-id pub-id-type="doi">10.1186/s13059-014-0489-9</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
